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ABSTRACT 
Neither licensed vaccines nor antiviral therapeutics with proven efficacy exist to protect against 
the equine encephalitis viruses (EEVs), specifically Eastern, Western, and Venezuelan Equine 
Encephalitis Viruses (EEEV, WEEV, and VEEV, respectively). Due to rigorous ethical, 
regulatory, and scientific considerations, animal models that can faithfully demonstrate aspects of 
clinical disease must be established for testing of countermeasure candidates. Such models must 
satisfy the Animal Rule promulgated and enforced by the United States Food and Drug 
Administration and capture key aspects of equine encephalitis virus presentation in humans, 
especially with respect to encephalitic disease, whose manifestations include fever and 
neurological signs.  
This study seeks to establish and study a model of human equine encephalitis virus 
infection via the aerosol route in the nonhuman primate, the cynomolgus macaque (Macaca 
fascicularis) with a focus on the natural history of disease through examination of radiofrequency 
electrocardiography data, and evaluates the feasibility of the use of such data to prognosticate 
severe disease courses which include encephalitis. Twelve nonhuman primate subjects, grouped 
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 v 
four per type of equine encephalitis virus, were challenged with aerosol exposures of the 
alphaviruses in various doses.  
The following electrocardiography metrics compose a core set of variables suited to the 
characterization of disease rendered by EEVs: HR, PCt, P-Width, PR-I, QRS, QRSA, QT-I, R-H, 
and RR-I.  Frequency spectrum analysis conducted on these metrics can be used to distinguish 
different periods of disease, if not distinguish between diseases, and Poincare plots of heart rate 
variability data can be used to track the progression of illness.  
The public health significance of this work rests in its contributions to disease detection to 
aid in vaccine and therapeutic development for both the prevention of infectious disease and the 
mitigation of risk posed by potential biological weapons attacks. Finally, improved clinical disease 
detection through RF telemetry and other markers will abet the surveillance function of public 
health. 
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1.0  INTRODUCTION 
1.1 THE NATURAL HISTORY OF EQUINE ENCEPHALITIS VIRUSES 
In the world of arthropod-borne viruses (arboviruses), equine encephalitis viruses (EEVs) compose 
a distinct portion of the alphavirus genera of the Togaviridae family of viruses. Alphaviruses, as 
detailed in Figure 1, consist of lipid-enveloped core icosahedral nucleocapsids enclosing ~101kb 
bicistronic nonsegmented, capped, and polyadenylated (+)ssRNA genomes with viral particles 
ranging from 60-70nm in diameter [1-3]. The alphavirus genome encodes four nonstructural 
proteins and five structural proteins, three of which, the capsid (C), and envelope proteins (E1, E2) 
have well-characterized functions [3, 4]. Subsequent to viral entry by receptor-mediated 
endocytosis, translation of nonstructural proteins begins immediately after the 
 
Figure 1. Alphavirus Structure. 
 2 
unpacking of the virion; these nonstructural proteins, encoded by genes near the 5’ end of the 
genome, generate a complementary (-)ssRNA transcript, from which novel (+)ssRNA progeny 
genomes are generated [5]. Concurrently, the nonstructural proteins also generate a subgenomic 
RNA which is translated to yield the structural proteins; all structural gene products, following 
necessary posttranslational modification, are then packaged into progeny.  
Alphaviruses can be further subdivided into New World and Old World groups. Eastern 
Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), and Western 
Equine Encephalitis Virus (WEEV) form three viral complexes of most interest in the New World 
group of viruses and constitute the focus of this project, as detailed in Figure 2 [2, 3, 6, 7]. These 
equine encephalitis viruses were the first alphaviruses to be isolated through the 1930s, and remain 
medically important pathogens unto the present day [5, 8-11].   
 
 
Figure 2. Equine Encephalitis Viruses. 
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Encephalitis here defines an infection of or inflammation of the brain parenchyma made 
manifest to observers by abrupt or subtle changes in brain structure or function [12]. Although 
humans inoculated with EEVs through mosquito bites may remain asymptomatic such that 
encephalitis is an uncommon finding, all three types of equine encephalitis virus can manifest with 
a febrile course (the length of which is dependent upon the virus), the eponymous encephalitis, 
and a variety of neurologic presentations including but not limited to photophobia, confusion, and 
seizures [1, 2, 12]. Survivors of virulent infections often develop lasting neurologic sequelae [1]. 
Symptoms range from nonspecific nausea, vomiting, diarrhea, and fever, to focal neurological 
signs or deficits, or altered mental status [1, 2]. The appearance of behavioral anomalies such as 
anorexia or depression is not uncommon [13]. More severe cases present with seizures, loss of 
consciousness, and coma [1, 2, 14]. Unlike the classical Wernicke’s Triad for bacterial meningitis 
which consists of fever, nuchal rigidity, and altered mental status, encephalitis of a viral origin 
rarely if ever presents with such a neatly-bundled profile of signs pointing to a viral cause of illness 
[12].  
Though post-mortem pathology can often render a definitive diagnosis of encephalitic 
etiology by examination of inclusion bodies, lymphocytic infiltrates, and staining, such methods 
cannot be used during the therapeutic window [15]. Although the most common cause of fatal 
nonepidemic encephalitis in the US remains herpes simplex virus I and II (HSV-1/2) encephalitis, 
enteroviruses are fast on the rise in terms of incidence in recent years [6, 12, 16]. Globally, other 
viruses, such as Japanese Encephalitis and West Nile Virus, are more commonly encountered than 
EEVs [1, 2, 5, 6, 13, 14, 17]. Differentiation of infection by EEVs requires a clear patient history, 
isolation of IgM or evidence of its conversion to IgG in cerebrospinal fluid, or confirmation by 
nucleotide amplification assay (reverse transcription PCR) in either blood, available tissues (in a 
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limited time frame), or CSF [13, 14, 18]. Radiological findings in the thalamus and/or basal ganglia 
can also confirm the presence of an EEV infection [14]. A summary table of the equine 
encephalitides discussed in this work is shown in Table 1. 
 
Table 1. Equine Encephalitis Viruses and Encephalitides. 
Virus Discoverer(s) 
Year of 
Discovery 
Disease and Encephalitis 
EEEV Meyer, Haring, & Howitt [9] 1931 
Presentation with sudden onset of fever and myalgia; seizures and coma occur with 
severe cases. In fatal cases, vascular damage observed in end-organs, including brain 
parenchyma. 4-10d latency via mosquito bite, 3-4d latency via aerosol [19, 20]. CFR 
50-70% [1, 2]. 
WEEV Broeck & Merrill [8] 1933 
Presentation with sudden onset of fever, headache, anorexia, malaise, and altered mental 
status. Encephalitis characterized by vasculitis and focal hemorrhages in basal ganglia 
and thalamus. Often lasting neurological deficits. Variable profile of apparent disease 
according to age. 2-7d latency via mosquito bite [19]. CFR 3-4%. 
VEEV Beck & Wyckoff [11] 1938 
Most commonly reported EEV in humans. Severe encephalitis less common than in 
EEEV or WEEV. Often asymptomatic, or presents as mild flu-like illness. Neurological 
disease or encephalitis detected in ~14% of infected individuals with a predilection for 
children and infants. 5-7d latency following mosquito bite [19]. 2-3d latency via 
aerosol; highly infectious via aerosol route. CFR<1% [19]. 
 
1.1.1 Eastern Equine Encephalitis Virus 
Eastern Equine Encephalitis is primarily borne by the Culiseta melanura mosquito vector, and 
covers the eastern United States as well as parts of South America [2, 21]. Other species of 
mosquitoes of the Aedes, Coqueillettidia, and Culex genera can also carry the virus, though with 
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decreased frequency [21, 22]. Areas particularly high in virus burden include freshwater 
swamps/estuaries, and tree farms [1]. Four subtypes of EEEV exist: I-IV; type I is the most lethal, 
and circulates mainly in North America, while types II-IV predominate in South America and 
present significantly fewer concerns for virulent human disease [20, 23]. Natural infections 
typically occur in the summertime, and are relatively infrequent, although a notable increase in 
cases and vector range over the past decade have variously been attributed to climate change and 
increased virus viability through the winter in avian enzootic hosts[6, 24].  
EEEV is notable for its high case fatality rate, which ranges from 30-70% in human hosts 
[25, 26]. Clinically, the incubation period is 4-10 days, sometimes with a prodrome of nausea, 
vomiting, fever, and headache[14, 17, 19, 25]. Across all subtypes, only 2% of adults and 6% of 
children progress to encephalitis, the onset of neurological symptoms heralds rapid deterioration, 
and the patient can become comatose. Other neurological signs include seizures and focal cranial 
nerve involvement. In the cerebrospinal fluid, a marked pleocytosis is observed, with a 
granulocytic (neutrophilic) predominance and elevated protein [13, 14]. One case series suggests 
that hyponatremia and pleocytosis in CSF lead to poor outcomes and a single case study points to 
viral myocarditis as a manifestation of EEEV infection [17]. Notably, treatment in humans with 
anticonvulsants and corticosteroids can result in worse outcomes [1, 2]. EEEV also presents a great 
risk of infection in aerosol form as well; a previous study in cynomolgous macaques demonstrated 
a dose-response relationship to the severity of aerosol-induced disease, and that at high doses, 
symptoms began to manifest within 72-96 hours of infection, with 100% lethality [20]. In 
examination of pathology in fatal human cases, lesions appear in the basal ganglia and thalami, 
suggestive of edema, ischemia, and/or hypoperfusion [14]. 
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1.1.2 Western Equine Encephalitis Virus 
Western Equine Encephalitis exists throughout the two American continents (in North America, 
mostly west of the Mississippi River); unlike the other two EEVs discussed, WEEV has not created 
the same number of case reports over the past decade, suggesting decreased virulence in humans 
or improved control though recent evidence suggests the latter through climate trends and 
agricultural industrialization practices [27]. Carried in North America by Culex tarsalis, WEEV is 
also significantly less virulent than EEEV, carrying a case fatality rate of 3-4%; however, 
documented reports of laboratory incidents with probable aerosol routes of infection portend a 
mortality rate of 40% [1, 2, 13, 28].  
In a reversal of observations from the other two EEVs, the encephalitic presentation is more 
severe in older adults, though infants and children are more prone to permanent neurological 
damage [13]. The prodrome lasts for 1-4 days, and signs and symptoms that arise can fit a profile 
similar to that seen in EEEV. Encephalitis and neurological deficits become apparent with 
confusion or altered mental status, tonic-clonic seizures, and coma [19]. Progression to 
encephalitis results in focal neurologic deficits similar to, but reduced in severity compared to 
those seen in EEEV, and blood work demonstrates a rise in granulocytes [1, 2, 28]. Another 
similarity between EEEV and WEEV exists in that WEEV appears to damage the basal ganglia 
and the thalamic nuclei as well, with characteristic vasculitides and focal hemorrhages in the gray 
and white matter that may be confused for cerebral infarcts [19]. 
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1.1.3 Venezuelan Equine Encephalitis Virus  
Venezuelan Equine Encephalitis is the most well-researched EEV to date, and is known for its 
high infectivity via aerosol [29]. The enzootic ID, IE, and II subtypes present the most concern for 
human disease [1, 2, 19]. In contrast to EEEV, VEEV is not as lethal, and with respect to 
transmission dynamics, equines serve as amplification hosts, while a large number of probable 
mosquito vectors exist, such as Culex, Aedes, and Mansonia, spp [1, 2]. VEEV preferentially 
prefers lymphoid tissues for replication, and seeds the peripheral CNS through the olfactory 
system, regardless of whether the virus was delivered subcutaneously or by aerosol [30, 31].  
The literature highlights pathologic changes in humans such as loss of neurons to apoptosis, 
neutrophilic penetration into the CNS, as in EEEV, and vasculitides in the CNS[13]. Presentation 
typically includes, apart from a nonspecific flu-like myalgia, a state of confusion or stupor, aphasia 
or mutism, muscular abnormalities such as involuntary movements and myoclonus, as well as 
ataxia [32]. Cranial nerve dysfunction can arise in the form of facial weakness, ocular palsies, 
photophobia, and nystagmus [32]. VEEV infection can manifest clinically as a febrile illness after 
a latent period ranging from a day to a week, and can be found early on by throat swabs, although 
the same diagnostic procedures and criteria as mentioned for the other two EEVs should be 
followed [5, 13, 28]. Mortality in humans from infection by VEEV is rare; however, for the 1% of 
adults and 4% of children who progress to encephalitis, associated events such as nuchal rigidity, 
ataxia, and convulsions may occur [1, 2, 28, 30]. A macular rash or arthritis can be seen in some 
cases, particularly around the distal extremities of the affected individuals [6, 13, 33]. Acute 
symptoms typically subside after four to six days, with complete resolution of the disease seen 
within one to two weeks, though neurological sequelae can persist [1, 2, 13].  
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1.1.4 Disease Pathogenesis by Aerosol Route  
The pathogeneses of the equine encephalitis viruses share much in common. As with all 
alphaviruses, during the natural course of infection by the mosquito vector, the pathogen enters 
the human host subcutaneously and invades cells via heterodimeric trimers of glycoprotein in the 
lipid envelope termed E1 and E2 that initiate receptor-mediated endocytosis [1, 2, 33]. In the skin, 
the viruses display a particular affinity for Langerhans dendritic cell receptors DC-SIGN and L-
SIGN [1]. The viral genome is released into the cytoplasm and viral reproduction occurs as 
discussed previously. Systemically, in a dead-end vertebrate host, virus inhibits the JAK/STAT 
pathway, allowing for evasion of the innate immune response, buying time for it to replicate and 
penetrate into the bloodstream to culminate in a detectable viremia [1, 4].    
A growing body of research continues to support and expands upon the notion that the 
route of exposure influences not only disease presentation but specifically viral pathogenesis [31, 
34, 35]. Although dissemination of the virus throughout the body by means of the viremia 
discussed above, the time at which this occurs is chiefly determined by the route of exposure, with 
the notable exception of VEEV [30]. Neuroinvasion by EEVs may occur before or after the 
establishment of viremia, and this can impact the severity of disease, especially in terms of the 
manifestation of encephalitic disease.  
All three equine encephalitis viruses eventually establish a bloodborne viremia; in this 
mode of infection, entry into the brain parenchyma, if not initiated by trafficking through the 
olfactory bulb, is thought to occur by the dissemination of the virus into the choroid plexuses or 
through the infection of the aforementioned astrocytes that compose the blood-brain barrier [15, 
36]. The end-organ damage and vasculitides described above suggest viral deposition by way of 
disruption of the integrity of the vasculature; the respiratory tract presents a large surface area for 
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infection to occur, with ready access to the vasculature through the mechanism of vertebrate gas 
exchange [34, 37-39]. 
A hypothesis expanded upon over the past few decades suggests that with respect to 
inhalational or aerosol exposure to viruses or other pathogens or toxins, the infection of the CNS 
and the induction of encephalitis can occur via trafficking of the agents through the neurons and 
support cells of the olfactory bulb, cranial nerve I (CNI) [26, 31, 34, 35, 40]. This hypothesis, 
hereafter referred to as the olfactory bulb hypothesis, proposes that the EEVs can access the 
olfactory sensory neurons embedded in nasal airway neuroepithelium; this concept is illustrated in 
a simian cross-section in Figure 3 [26]. The neural projections contained in the neuroepithelium 
connect the oronasal cavity in primates directly to the central nervous system; 
 
 
Figure 3. Olfactory Hypothesis.  
A primate model. Inhalational infection of nasal neuroepithelium facilitates the seeding of the CNS with infectious 
particles through cranial nerve projections. The red lines represent the flow of infectious particles.  
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when this tissue encounters viral particles, olfactory receptor neurons and sensory neurons from 
the trigeminal nerve (cranial nerve V, CNV) are susceptible to viral entry [26, 41, 42]. Virions can 
also infect the lamina propria of this layer of tissue, accessing blood vessels and lymphatic tissue. 
The projections transit through the base of the cranial vault and into the brain proper by way of the 
cribriform plate in the ethmoid bone; cell-to-cell transmission in the CNS can then take place, 
between various cell types such as neurons, oligodendrocytes, and astrocytes, the last of which are 
notable for their role in the blood-brain barrier [41, 42].  
1.1.5 Treatment and Prevention of Equine Encephalitis Viruses 
Therapies for EEV currently consist of supportive treatment, and the use of human monoclonal 
antibodies; however, no licensed treatments exist [43]. With respect to prevention, while veterinary 
vaccines exist for equines, and prophylactic application in horses in the United States is highly 
recommended (though not strictly required), no licensed vaccines currently exist for broad use in 
humans [1, 2]. The exception to this lies in the availability of EEV vaccines for laboratory workers 
at increased risk of exposure to these pathogens; one of the fruits of the US biological weapons 
program lay in the development of two VEEV vaccines: TC-83 (for Tissue Culture, 83 passages), 
an attenuated strain of VEEV, and C-84 formalin-inactivated vaccine for VEEV [44]. Neither 
vaccine is licensed, and are both administered only under investigational new drug (IND) rules, 
but the vaccines have been proven to confer time-limited protection against VEEV, and may 
require booster doses for prolonged efficacy. Though formalin-inactivated vaccines also exist for 
WEEV and EEEV, no vaccine has achieved proven efficacy against WEEV or EEEV. These latter 
vaccines are also administered as INDs, and neutralizing antibody titer is used to determine 
immunity. 
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1.2 A NONHUMAN PRIMATE MODEL OF EQUINE ENCEPHALITIS VIRUS 
AEROSOL INFECTION 
1.2.1 A Cynomolgus Macaque (Macaca fascicularis) Model of Aerosolized EEV Infection  
1.2.1.1 FDA Animal Rule  
The risks posed by EEVs both from seasonal/incidental infections by a bridge or epizootic vector 
and from the intentional use of aerosolized EEVs as biological weapons make the case for further 
study of these diseases. The mouse model falls short not only in the approximation of human 
anatomy, but also presents challenges with generalizability of findings to humans in comparison 
to the phylogenetically closer nonhuman primates. In light of the contextual risks, and due to the 
fact that no extant non-animal model exists which can replicate to a high degree of fidelity and 
robustness of a respiratory and systemic biological response to an aerosolized alphavirus infection, 
an inhalational nonhuman primate model for EEV infection represents a highly desirable goal for 
the continued study of EEV-type alphaviruses.  
1.2.1.2 Nonhuman Primate Encephalitis Model Motivation and Rationale 
The lasting neurological sequelae from survivors of symptomatic EEV disease are poorly 
characterized; their profiles are defined by aggregate case series and case reports collected 
incidentally following isolated outbreaks rather than by systematic reviews of the literature, and 
no definitive doctrine governs the management of the diseases or the aforementioned sequelae, 
though proof-of-principle treatments both specific and nonspecific, as well as some prophylactic 
interventions exist [43, 44].  
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To date, human infections with aerosolized EEVs remain relatively uncommon, 
unreported, or unrecognized. Of the known human cases, most have arisen in accidental exposures 
of laboratory workers and personnel [44]. Currently, diagnosis relies upon a high index of clinical 
suspicion given a patient’s geographic location and/or travel history; in the case of attack by a 
biological weapon, these methods may prove insufficient to capture diagnoses in a timely manner. 
EEV encephalitis remains nonspecific for the diagnosis of any particular EEV, not least because 
its presentation shares a similar profile with that of other diseases, such as West Nile Virus, St. 
Louis Encephalitis, and other flaviviruses. Perhaps the most reliable indicator of an active or 
previous infection lies in serological testing for either EEVs themselves through reverse 
transcriptase PCR (RTPCR) or through detection of virus-specific antibody through enzyme-
linked immunosorbent assays (ELISA) [18]. Similarly, detection of either sufficient virus or 
antibody in the CSF is diagnostic.  
Animal models of disease for the advancement of knowledge have been in use since the 
days of Aristotle; in the case of simulating the encephalitis in humans wrought by the various 
equine encephalitis viruses, much work has been performed in the murine model [45]. Although 
mice retain many similarities with humans, infection with EEV aerosols tends to produce much 
more virulent disease in mice, particularly for VEEV, blunting the usefulness of the murine model 
for direct analogy to human disease [27, 31, 34, 36, 46, 47].  
Certain species of nonhuman primates, such as rhesus (M. mulatta) and cynomolgus 
macaques (M. fascicularis), have been well-characterized with respect to anatomy and physiology, 
as well as to immune responses in the contexts of diseases caused by a multitude of infectious 
pathogens [20, 28]. Studies with EEVs in rhesus and cynomolgus macaques date back to the 1930s; 
these studies demonstrated that intranasal inoculation with EEEV and WEEV could cause fatal 
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encephalitis. The cynomolgus macaque as a model organism provides a distinct advantage due to 
its pattern of susceptibility to EEVs and the structural similarity and tissue composition of the nasal 
epithelium in macaques to that of humans [20, 28, 38, 41, 42]. A body of work has demonstrated 
that infection of macaques by various means including but not limited to subcutaneous and aerosol 
routes of infection can reproduce lesions in the brain that recapitulate those produced during the 
course of an infection by an equine encephalitis virus in human cases [20, 28, 30, 48]. Since each 
of the EEVs pose potential threats as weaponized agents, the goal of reproduction of encephalitic 
disease by the respiratory route remains paramount. Not only will the faithful recapitulation of 
clinical markers and histopathology of encephalitic disease advance the body of knowledge 
regarding the clinical course in species substantially phylogenetically closer to humans, it will also 
provide for a testbed suitable for the study of vaccines and therapeutic agents due to its ascendant 
relevance to human disease.  
1.2.2 Radiofrequency Telemetry – Electrocardiography  
Radiofrequency telemetry serves as a method of monitoring for encephalitic disease in animal 
models and has been successfully implemented in previous work [20, 34, 49]. The EEVs, upon 
induction of encephalitic disease, will generate clinical signs that can be monitored by direct 
observation, and can manifest a febrile illness, which may be monitored remotely by a discrete or 
continuous stream of data. A wealth of other physiological parameters, such as 
electroencephalography (EEG) and electrocardiography (ECG) can be used to track the course of 
disease as well.  
The ability to complement observations of the test subjects with a sustained feed of 
electrophysiological data provides an improved ability to monitor the model organisms. 
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Radiofrequency telemetry can enhance the clinical relevance of data, and can perhaps provide 
prognostication of whether or not an animal will manifest with signs of encephalitic disease. 
Indeed, in the encephalitic disease state, though temperature remains the foremost method of 
tracking fever, it is too nonspecific a measure to exclusively implicate encephalitis. Replication of 
virus in the periphery can also present with fever; other measures, such as those provided by 
analysis of ECG data, have not yet been explored for the purposes of tracking encephalitis. 
Although a fair degree of correlation exists between an increased core temperature and other 
physiological parameters, the examination of those other previously unexamined parameters can 
add multiple dimensions to the knowledge of encephalitic disease. 
Regardless of the mechanism by which EEVs access the central nervous system, the brain 
is undoubtedly affected, with specific attention paid to the basal ganglia and the thalamus, as 
previously described. Infection of the brain through the hypothesized olfactory bulb route provides 
a route for penetration into the hypothalamus, which receives olfactory cues, among other inputs 
[31, 36, 39, 41, 42, 50, 51]. The hypothalamus plays an integrative role in maintaining homeostasis 
in almost all aspects of vertebrate physiology, and is fairly robust in handling perturbations to the 
system in a healthy animal; it is further subdivided into a number of nuclei responsible for specific 
functions such as those governing wakefulness and appetite [50, 51]. At a more tangible level, the 
hypothalamus controls the autonomic nervous system by regulating sympathetic and 
parasympathetic output, to regulate global parameters in the body, including vasoconstriction, 
secretion from glands, and heart rate [50, 51]. Although the heart retains its own local, specialized 
pacemakers in the form of the sinoatrial (SA) and atrioventricular nodes (AV), normal 
physiological function relies on a delicate balance of sympathetic and parasympathetic output 
regulated by the hypothalamus; encephalitic disease that penetrates into the CNS will most 
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certainly directly or indirectly induce hypothalamic dysregulation [5, 26, 33, 50, 51]. This 
proposed mechanism underlines the value of monitoring electrocardiographic data as a surrogate, 
sentinel, or prognosticator of encephalitic disease, notwithstanding the manifestation of 
electrocardiographically detectable events suggestive of direct end-organ damage by the EEVs. 
1.2.2.1 Principles of Electrocardiography  
The mammalian heart is composed of a unique type of muscle, cardiac myocytes. Cardiac 
myocytes are conductive, and form a cardiac syncytium linked by gap junctions in a spatially 
oriented manner, such that electrical impulses from action potentials result in coordinated 
contraction of muscle. Cardiac anatomy separates the circulation into two parallel circuits of blood 
flow: deoxygenated blood travels from the heart to the lungs and back, and oxygenated blood 
travels from the heart to supply all tissues.  
William Einthoven in the early 1900s devised a method of monitoring heartbeat through 
the directional detection of electrical impulses over the surface of the skin, and perfected the 
method through the century [52]. Consider the ECG diagrams in Figure 4. At its core, the 
electrocardiogram generated by a single heartbeat provides the PQRST (defined below) profile of 
an atrial and ventricular contraction and repolarization. From this signal, different segments of the 
waveform may be used to compute several key measures that provide insight into various aspects 
of cardiac physiology. The P wave corresponds to the depolarization of the atria, the QRS complex 
corresponds to both ventricular depolarization and atrial repolarization, and the T wave represents 
ventricular repolarization. The entire complex represents one heartbeat. Voltage-gated, 
inactivating sodium channels prevent backward flow of electrical current. Gross abnormalities in 
electrical conduction due to abnormal tissue growth or scarring become evident when viewed on 
 16 
an electrocardiogram, and the rate and rhythm can raise red flags for other cardiac pathologies, as 
well.  
 
Figure 4. ECG Waveforms from M. fascicularis with Relevant Physiological Parameters. 
 
Data from a study performed in the 1980s provide the most complete set of information 
regarding the characteristics of ECG waveforms in M. fascicularis; however, as the authors used 
traditional 12-lead ECG to conduct these studies, the macaques required sedation, which may have 
masked the true baseline values [53]. Perhaps the most basic consideration is the heart rate (HR); 
in the various literature reviewed, the resting HR of cynomolgus macaques in laboratory conditions 
appears to range from 150-250 beats per minute, roughly twice that of human adults, but relatively 
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normal for human infants [53, 54]. Heart rate is constructed from the RR-interval (RR-I), defined 
as the interval of time between two beats of the heart, which is calculated continuously. In 
conjunction with other biological information, ECG can help construct clinically relevant 
conclusions regarding such matters as the hydration status of the animal and the state of the 
subject’s autonomic function [51]. Furthermore, the information used to calculate heart rate can 
also be used to monitor heart rate variability (HRV). HRV represents the variation in the time 
interval between heartbeats, expressed in units of interbeat interval (ms) [55]. Diminished HRV is 
associated with such pathology as DM neuropathy, heart failure, and generalized stress. Again, 
this provides insight into the hypothalamic regulation of heart rate during the sleep-wake cycle.  
Other measures of interest include the QT-interval (QT-I); it documents the time elapsed 
between the Q wave of the ECG trace and the end of the T wave. QT-I can further be subdivided 
into the QRS complex and the ST interval/segment (ST-I). Elevation of the magnitude of the signal 
over the ST segment (ST-E) has traditionally been used to detect myocardial infarctions in clinical 
settings. The PR-interval (PR-I) can provide insight into the integrity of the electrical conductivity 
of the atrial myocardium, informing on conditions such as atrial-ventricular conduction block. 
Notably, the PR-I was found to vary with HR in M. fascicularis, which differs from conventional 
doctrine regarding PR-I in humans; however, given the typical short length of the PR-I in the 
animal model, 80ms, such variation may not hold any implications for statistical significance [53]. 
For ventricular contraction, the QRS complex (QRS) can denote whether or not pathology is 
disrupting the speed with which ventricular contraction occurs. The T-Wave has many metrics 
associated with it, such as the time between the peak and end of the T-wave (T-Pe), which examine 
the repolarization of the ventricles of the heart, and can identify problems affecting the speed of 
repolarization, such as ischemia in the various layers of myocardium. 
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1.2.2.2 Other Telemetric Monitoring of Clinical Course 
Intuitively, continuous monitoring of temperature in a macaque serving as a model for a febrile 
illness presents a highly desirable modality, such that a profile of the fever itself may be generated 
and analyzed. Several articles have documented that in the case of EEEV, VEEV, and WEEV 
infections, marked temperature elevations occur, ranging from 0.5-2.0oC depending upon the virus 
and the dose given [1, 20, 25, 28]. Moreover, temperature can provide insight into whether or not 
subjects have entered a state of terminal decline, as hypothermia may afflict moribund individuals. 
The prime importance of temperature lies in its ease of observation, status as a cardinal clinical 
vital sign, and its ability to define the period of frank illness in the NHP model.  
The temperature, as discussed previously, can also vary collinearly with 
electrocardiographic signals. A manuscript in preparation at the time of this writing by Reed 
suggests that in disease states induced by infectious disease (B. anthracis, Y. pestis, EEEV, 
WEEV), HRV becomes decoupled from temperature. Published work by Reed, et al. broached the 
use of telemetry by taking measurements of temperature every 15 minutes to record subjects’ body 
temperature over the disease course [20].  
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2.0  SPECIFIC AIMS 
The work precipitating this project lies in the characterization and establishment of a primate 
model of EEV-attributable disease, to investigate the pathogenesis and course of aerosol-induced 
encephalitic EEV illness, and to use the information obtained towards the development and testing 
of safe and efficacious treatments or vaccines. Goals primary to the completion of the project 
include investigation of dose-response relationship between clinical and telemetric signs observed 
and dose of virus administered, and to evaluate the utility of electrocardiographic surveillance of 
the disease course as indicators of encephalitis and disease outcome. The leading goals of this 
work revolve around the study of the characterization of the natural history of disease through 
electrocardiographic monitoring following the aerosol exposure of nonhuman primates to EEVs. 
Pursuant to the continued development of the cynomolgus macaque as a model for aerosolized 
alphavirus infection, this thesis will consist of analyses and investigation in concordance with a 
pair of multi-part specific aims.  
2.1 SPECIFIC AIM 1: TO ESTABLISH A SET OF TELEMETRIC PARAMETERS 
THAT ACCOMPANY THE COURSE OF ILLNESS 
The scope of this project lies in the investigation of the natural history of disease through the 
monitoring of electrocardiography. Thus, the establishment of a core set of telemetric parameters 
that can aid in the determination of the course of illness for each type of equine encephalitis virus 
comprises a primary aim of this work. Therefore, subparts of this aim include: 
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a.  Determine which electrocardiographic parameters are relevant to or reflect the 
progression of disease.  
 
b.  Establish a basis of analytical comparison of telemetry parameters to distinguish 
between sick and well states. 
2.2 SPECIFIC AIM 2: TO ASSESS DISTINGUISHING FEATURES OF EQUINE 
ENCEPHALITIS VIRUSES WITH RESPECT TO TELEMETRY SIGNATURES 
Similarly, pursuant to the development of the cynomolgus macaque as a model for aerosolized 
infection of equine encephalitis viruses, drawing comparisons between differing disease courses 
through analysis of the telemetry data remains fertile ground for investigation. Therefore, subparts 
of this aim require the: 
 
a.  Establishment of a basis of comparison of telemetry parameters to characterize EEEV, 
WEEV, and VEEV courses of illness.  
 
b.  Determination of whether telemetry metrics prognosticate or correspond to subclinical 
physiological or behavioral responses with onset and severity of encephalitis.  
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3.0  MATERIALS AND METHODS 
This investigation occupies a niche of a larger project: “Improved nonhuman primate models of 
inhalational alphavirus infections for use in preclinical evaluation of novel therapeutics,” IACUC 
protocol 16026773, funded by Department of Defense (DOD) – Army grant number/project ID 
W911QY-15-1-0019. This study was fully approved by the University of Pittsburgh IACUC, and 
research is fully compliant with rules, regulations, and recommendations stipulated by the Animal 
Welfare Act and the Guide for the Care and Use of Laboratory Animals. The University of 
Pittsburgh, which includes the regional biocontainment laboratory (RBL), is fully accredited by 
AAALAC International. 
3.1 GENERAL BIOSAFETY AND SELECT AGENT HANDLING 
Biological safety is key to handling any pathogen. Virus culture was performed under BSL-3 
conditions for Eastern, Western, and Venezuelan Equine Encephalitis Viruses in Class II biosafety 
cabinets with appropriate use of a 1:128 phenol-based Vesphene IIse (Steris Corporation, Catalog 
No. 646101) to water dilution for disinfection. Aerosol procedures were performed in a Class III 
biosafety cabinet modified with apparatus appropriate for transport and containment of animal 
subjects, within the Aerobiology Suite in the University of Pittsburgh Regional Biocontainment 
Laboratory (RBL). In animal suites within the RBL, wherein both animal subjects and telemetric 
monitoring equipment were housed, powered air-purifying respirators (PAPRs) were worn in 
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addition to Tyvek® high-density polyethylene (HDPE) hooded coveralls, rubberized boots, and 
double layers of nitrile gloves as personal protective equipment.    
Due to the classification of EEEV and VEEV as select agents as outlined by the United 
States Select Agent List, laboratory work with these pathogens must be conducted within the BSL-
3 laboratory of a facility registered with the Centers for Disease Control’s Division of Select 
Agents & Toxins (DSAT).  
3.2 VIRUS CULTURE AND CHARACTERIZATION 
The selection of virus strains in these studies was made by the Department of Defense in 
conjunction with the Food & Drug Administration. For FDA Animal Rule studies, human isolates 
of virulent pathogens are preferred. The EEEV used in this study was the V105 strain of Eastern 
Equine Encephalitis Virus; WEEV used in this study was the Fleming strain; and the VEEV used 
in this study was the INH-9813 strain on the IC epizootic subtype. All alphavirus stocks were 
generated through construction of cDNA clones by Dr. William Klimstra’s laboratory; capped, 
infectious viral RNAs were generated by in vitro RNA synthesis from linearized cDNA plasmid 
template genomes that were electroporated into baby hamster kidney (BHK-21, ATCC) cells. The 
supernatant was clarified by centrifugation between 18-24 hours post-electroporation, and single-
use aliquots were stored at -80oC to create zero-passage (p0) stocks. These p0 stocks were titered 
by standard plaque assays on BHK-21 cells. The p0 stocks were then used to infect roller bottles 
containing kidney cells from African Green Monkey (VERO cells, ATCC CCL-81) at a 
multiplicity of infection of 10. At 18-24 hours post-infection, the supernatant was clarified by 
centrifugation and then subjected to sucrose purification. Supernatant was carefully layered over 
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a 20/60% sucrose cushion and subjected to ultracentrifugation. The interface between the 20/60% 
sucrose cushion was collected and then diluted in 10mM Tris, 1mM EDTA, 100mM NaCl - STE 
10X NaCl (TNE) buffer. The interface was then layered over 20% sucrose and again subjected to 
ultracentrifugation to pellet the virus. The pelleted virus was then resuspended in Opti-MEM® 
Reduced Serum Medium (ThermoFisher, Cat. No. 31985-070) and single-use aliquots were stored 
at -80oC. The virus stock was then tittered using standard plaque assays on BHK-21 cells and the 
LD50 was confirmed in mice by Dr. Klimstra’s laboratory before being used for NHP studies. 
3.3 AEROSOL CHALLENGE AND DOSE DETERMINATION 
3.3.1 Aerosol Challenge 
 For each aerosol challenge, aerosol generation was performed in a modified Class III biosafety 
cabinet specially outfitted with apparatus for work in aerosol generation and aerobiology.  The 
platform housed in the cabinet consists chiefly of the AeroMP aerosol management platform 
(Biaera Technologies, Hagerstown, MD). A robust, automated system, Aero MP creates a highly 
controlled environment for the administration of EEVs to the animal subjects by implementing 
computer control of cabinet barometric pressure, humidity, subject plethysmography/spirometry, 
and exposure duration to minimize differences in inhaled doses delivered to individual macaques. 
In preparation for the aerosol, each subject received anesthesia consisting of 6 mg/kg 
Telazol® (Tiletamine HCl / Zolazepam HCl), and was weighed. Blood was drawn for analysis of 
clinical chemistry and complete blood count (CBC) with the Abaxis VetScan VS2 and HM2, 
respectively. Each subject was then transferred into the modified Class III biosafety cabinet. 
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Respiratory Inductive Plethysmography (RIP; Data Sciences International (DSI), St. Paul, MN) 
belts were attached to the macaque’s chest and abdomen to record respiratory function via 
Ponemah software (DSI). Macaques were exposed for 10 minutes inside an acrylic head-only 
chamber to an aerosol of EEEV, WEEV, or VEEV, created with an Aeroneb vibrating mesh 
nebulizer (Aerogen, Chicago, IL) Aerosol exposures were controlled and monitored using the 
Aero3G exposure system (Biaera Technologies, Hagerstown, MD). Aerosol sampling to determine 
presented dose was done with an all-glass impinger (Ace Glass, Vineland, NJ). Each aerosol was 
followed by a 5-minute air wash. Throughout the aerosol challenge, each NHP received a 
continuous infusion of ketamine (at the rate of 10 mg/kg/hr) to maintain the anesthetic effect 
brought upon by the initial Telazol knockdown. The aerosol challenge apparatus as configured in 
the Class III biosafety cabinet is illustrated in Figure 5.   
 
Figure 5. Schematic of AeroMP Aerosol Apparatus. 
Modified from Lackemeyer, et al [56]. Vacuum pulls air through the HEPA-filtered apparatus in the biosafety cabinet. 
Virus is loaded into Aeroneb nebulizer, which is activated via external computer control. Vibrating mesh generates 
aerosol, which is pulled into mixing tube and into the head-only chamber wherein macaque awaits exposure.  
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3.3.2 Dose Determination 
Plaque assays with BHK-21 cells were done on samples collected in an all-glass impinger (AGI; 
Ace Glass, Vineland, NJ) during the aerosol to determine the aerosol concentration and presented 
dose. Aerosol concentration was calculated as the product of the virus concentration in the AGI 
multiplied by the volume of liquid in the AGI divided by the product of the flow rate of the AGI 
(6 Lpm) and the duration of the exposure. Presented dose (i.e. inhaled dose) is calculated as the 
product of the aerosol concentration, the minute volume of the macaque and the duration of the 
exposure. All cells were grown at 37oC with 5% CO2. Calculated doses for aerosol challenges for 
EEEV, WEEV, and VEEV are listed in Table 2.   
Table 2. Doses of Equine Encephalitis Viruses Given During Aerosol Challenges. 
Nonhuman Primate Virus Aerosol Date Dose Received (PFU) 
M160-16 ♂ (1st Aerosol) EEEV V105 08/26/2016 1.10 x 107 
M160-16 ♂ (2nd Aerosol) EEEV V105 10/06/2016 2.98 x 108 
M161-16 ♂ EEEV V105 10/14/2016 1.60 x 108 
M162-16 ♂ EEEV V105 10/28/2016 4.64 x 105 
M163-16 ♂ EEEV V105 09/02/2016 3.39 x 107 
M164-16 ♀ VEEV INH-9813 11/04/2016 1.27 x 108 
M165-16 ♀ VEEV INH-9813 11/04/2016 7.88 x 106 
M166-16 ♀ WEEV Fleming 01/30/2017 9.88 x 107 
M167-16 ♀ WEEV Fleming 01/30/2017 2.89 x 108 
M168-16 ♀ WEEV Fleming 02/13/2017 2.21 x 107 
M169-16 ♀ WEEV Fleming 02/13/2017 3.76 x 107 
M170-16 ♂ VEEV INH-9813 01/09/2017 2.22 x 106 
M171-16 ♂ VEEV INH-9813 01/09/2017 1.02 x 106 
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3.4 RADIOFREQUENCY TELEMETRY AND DATA COLLECTION 
3.4.1 Radiofrequency Electrocardiography 
Telemetry data from twelve healthy, adult cynomolgous macaques (Macaca fascicularis) was 
collected continuously from DSI PhysioTel Digital radiofrequency transmitters (DSI Model No. 
M01) for a baseline period preceding aerosol challenge as well as for the days following the 
exposure to EEV. The transmitters were surgically implanted intra-abdominally in each animal at 
Covance Laboratories (Princeton, NJ) by a DSI veterinarian. ECG leads were sutured in place, one 
under the right pectoralis muscle and one parallel to the left inguinal area, approximating Lead II 
placement in a 12-lead ECG. The unit also contains a temperature sensor that samples core 
temperatures on a continuous basis, as well as an accelerometer designed to track the movement 
of the animal. The implanted unit itself is pictured in Figure 6. 
  
Figure 6. Radiofrequency Telemetry Electrocardiography Implant.  
 
 The collection apparatus, located inside the RBL, consisted of a designated telemetry 
computer outfitted with a communication link controller (CLC) supplied by DSI. The CLC was 
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optimized for collecting signals from transceivers mounted on caging containing singly-housed 
NHP subjects, with cameras positioned to record NHP behavior; the setup as described is detailed 
in Figure 7.  
 
 
Figure 7. Radiofrequency Telemetry Setup in toto. 
 
The Ponemah software package (v.5.2; Data Sciences International) provides a graphic 
user interface (GUI) that presents a unified, multichannel display of the data collected from the 
implant’s sensors. For analysis, data can be either read in raw form (.RAW file extension) or 
reviewed in common spreadsheet, statistical analysis, and plotting programs. Body temperature 
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and electrocardiographic measures including heart rate are sampled at 10 Hz and recorded every 5 
seconds [49]. Telemetric monitoring began for each NHP at least three days before exposure to 
the aerosol challenge to develop a baseline. For body temperature, recorded values outside two 
standard deviations of the mean were used to compute fever duration and cumulative fever-hours 
(cumulative total hours of signiﬁcant temperature elevations). Because of the potential for a high 
degree of variation in physiology, baseline data of relevant biological metrics were compiled into 
a study-population specific database to establish the baseline for this specific study population, 
viewable in Appendix A. A brief summary of available metrics are exhibited in Table 3; standard 
deviations of these metrics were also measured and recorded at the same sampling frequencies. 
 
Table 3. Electrocardiogram Metrics of Study. 
Electrocardiography Metric Abbreviation Significance Units 
Arrhythmic Beat Detection BAD The number of arrhythmic beats detected during a logging period.  Count 
Heart Rate HR Number of heartbeats per minute. bpm 
Heart Rate Variability HRV RR-Intervaln matched with RR-Intervaln+1, plotted as an ordered pair. 
ms, 
Unitless 
Maximum Voltage Derivative of R-
Wave MxdV 
Maximum rate of change of ECG trace 
at R-Wave. mV/ms 
Noise in ECG Trace Noise 
Approximation of noise level in ECG 
cycle; root-mean-square value of 
derivative in a single ECG cycle. 
Unitless 
P-Wave Count PCt Number of P-waves counted in one sample. Count 
P-Wave Height P-H Height of P-Wave from isoelectric level.  mV 
PR-Interval PR-I 
Interval of time between beginning of P-
Wave to the beginning of the R-Wave. 
Can detect atrial conduction block. 
ms 
P-Wave Width P-Width Interval of time from the P-Wave to the end of the P-Wave. ms 
QaT QATN Interval of time between the Q-Wave to the peak of the T-Wave. ms 
QR-Interval QR-I 
Interval of time between the Q-Wave to 
the peak of the R-Wave. Indicator of 
ventricular depolarization and/or 
contraction. 
ms 
QRS-Interval 
 QRS 
Interval of time between the Q-Wave to 
the beginning of the S-Wave. Indicator  ms 
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Table 3 (cont’d) 
  of ventricular depolarization and/or contraction.  
QRS Amplitude QRSA 
Amplitude of QRS complex from the 
isoelectric level. Indicator of ventricular 
contraction. 
mV 
QT-Interval QT-I 
Interval of time between the Q-Wave to 
the end of the T-Wave. Indicator of 
electrolyte status as well as speed of 
total cardiac repolarization. 
ms 
R-Wave Height R-H Height of the R-Wave from the isoelectric level.  mV 
RR-Interval RR-I Interval from one R-Wave peak to the next R-Wave peak. ms 
ST-Elevation ST-E 
Height of the T-Wave at 
algorithmically-determined point 
between S-Wave and T-Wave, to detect 
myocardial infarction. 
mV 
ST-Interval ST-I Interval of time between the S-Wave and the end of the T-Wave. ms 
T-Wave Height T-H Highest point between the end of the S-Wave and end of the T-Wave.  mV 
T-Wave Trough T-HN Lowest point between the end of the S-Wave and end of the T-Wave. mV 
Peak of T-Wave T-P 
Peak of T-Wave relative to isoelectric 
level, between end of S-Wave and end 
of the T-Wave. 
mV 
T-Wave Peak-to-End T-Pe 
Time between the peak of the T-Wave to 
the end of the T-Wave; indicator of 
ventricular reperfusion. 
ms 
 
3.4.2 Clinical Scoring for Encephalitis.  
To monitor signs of clinical encephalitis for nonhuman primates, animals were monitored at least 
twice daily following aerosol challenge. Generally, animals were monitored for stool and urine 
output and appropriate nonhuman primate behavior. Food consumption and water intake were 
closely monitored throughout the animals’ stay at the RBL. All EEVs were expected to cause a 
period of illness ranging in severity within a week after aerosol challenge. In the most fulminant 
of cases of EEV encephalitis, death due to febrile/encephalitic disease was expected within 2-3 
days of fever onset [20]. As mentioned previously, the clinical signs of illness, features of 
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EEEV/WEEV/VEEV, can include anorexia and dehydration with accompanying fever and/or 
encephalitis. Tremors, myoclonus, seizures, coma, nystagmus, photophobia, and many other 
clinical signs of note were flagged for observation, as well. 
Macaque subjects were thus given a clinical score during each (twice-daily) post-aerosol 
observation composed of three individual rankings: temperature, activity, and neurological status 
scores. Temperature scores were given on an ordinal scale of 1-6: 1 denotes a temperature between 
37-39oC, 2 denotes a febrile temperature over 39oC but below 40oC, 3 for a temperature over 40oC 
but below 41.5oC, 4 for temperatures over 41.5oC. As temperatures below 37oC indicate slight or 
severe hypothermia, common in moribund animals, temperatures between 35-37oC and 
temperatures below 35oC rank a 5 and a 6, respectively.  The neurological scores and activity 
scores were also ordinal scales of 1-6: a score of 1 constituted normal neurological function and 
activity; a score of 2 corresponded to occasional loss of balance, drooling, or muscle control, and/or 
photophobia, for neurological signs, and decreased body language interactions for the activity 
score. A score of 3 includes nystagmus, head pressing and tremors for neurological signs, and a 
sluggish response from the animal for the activity score. A score of 4 represents the presentation 
of occasional seizures for the neurological score, and an upright but otherwise completely 
unresponsive subject for the activity score. Frequent seizures warrant a neurological score of 5, 
while the same score for activity level is begotten by a recumbent or moribund animal; the latter 
triggers the humane endpoint for the study, discussed below. Finally, a comatose animal begets a 
neurological score of 6 and likewise prompts the humane endpoint for the study. These scores 
were formulated based off previous work in M. fascicularis subjects [20, 28, 57].   
Animals that scored a 10 or higher warranted an observation schedule with an increased 
frequency of observation: once every eight hours. If an animal reached a score of 14 or higher, the 
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humane study endpoint was triggered following principal investigator and veterinarian approval, 
and the animal euthanized by complete exsanguination via transcardial perfusion with 12L of 
sterile 0.9% saline following administration of 10 mg/kg ketamine, intravenous sodium 
nitroprusside diluted in heparin solution for maximum vascular vasodilation, and a sublethal 
intravenous dose of 15 mg/kg sodium pentobarbital. Death was confirmed by observed cardiac 
arrest, cessation of respiration, and corneal areflexia.  
3.5 ANALYSIS OF TELEMETRIC DATA 
Statistical analysis was performed through the use of MATLAB (MathWorks) in addition to Excel 
(Microsoft). Repeated measures ANOVA, one-way ANOVA (Tukey’s post-hoc correction) and 
pairwise t-tests were performed to compare each subject’s post-aerosol challenge metrics with pre-
challenge baseline metrics, daily and in aggregate, to compare metrics from the sick state from 
animals that became sick, to the well state, and to compare metrics from the febrile post-challenge 
period to the afebrile post-challenge period. To compare between different groups of subjects 
within one EEV subset, ANOVA was used to provide for more robust analysis of differences 
between discrete time periods (i.e. sick and well states) between animals challenged with the same 
EEV. Analyses of frequency-spectrum data were also performed to compare differences between 
different periods in relation to disease onset and pre-/post-aerosol samples. One-way ANOVA was 
used to assess differences in heart rate variability by day.   
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3.5.1 Data Processing 
Electrocardiographic measures were sampled at a rate of 10 Hz, recorded at a minimum interval 
of 5s; the volume of raw data printed at this rate proved too much for the processing capabilities 
of all forms of analytical software employed to plot and analyze the data, with the sole exception 
of MATLAB. However, even with the latter software package, processing was difficult due to the 
volume of data, and a one-minute standard for interval data was chosen, as an aggregate of data 
recorded every five seconds. Although an arbitrary choice, this interval proved manageable for 
computation times while still presenting a respectable maximum of 1440 data points per day from 
17280, an entire order of magnitude fewer.  
Timescales were converted from dd:hh:mm:ss format to a scalar days-post-infection frame 
for all NHP subjects. This was not essential, but greatly aided the establishment of pre- and post-
infection time frames. To do this, all time points were referenced to a canonical start time: the 
initialization of telemetry recording for M160-16 was considered the beginning of the study. This 
way, data could easily be converted from dd:hh:mm:ss from the initial start point into seconds, and 
from then, referenced to the time of the aerosol challenge to give days pre/post-infection, with the 
variable name “M1XX-16_DPI” for each NHP.  
Raw data was imported into Excel and variable names made palatable for importation into 
MATLAB and subsequent data processing. To tailor processing and comparisons, each variable 
name contained the subject number, sex, live/dead status, and the variable of interest. The template 
thus described: “M1XX-16_(M/F)_(E/W/V)_(L/D)_Var,” with M/F representing the sex of the 
NHP subject, E/W/V representing the EEV administered, and L/D representing the survival status 
of the macaque “L” for survived, and “D” for NHPs that reached the humane study endpoint within 
the course of post-challenge observation. The data were then ported into MATLAB, whereupon 
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data processing censored data that was missing, and likewise censored unphysiological values. 
Plots of all measures were generated against the disease course as measured by temperature 
profiles (plot of mean temperature in addition to cumulative fever-hours) and clinical scores.  
3.5.2 Establishment of Disease Courses 
To determine the periods for comparison within each nonhuman primate subject, temperature and 
clinical score profiles were plotted such that the periods prior to aerosol and post aerosol were 
clearly delineated. Although each NHP in effect served as its own control due to the small quantity 
of NHPs in each alphavirus group, the disease profiles were similar enough across multiple NHPs 
in each group, as noted in preliminary examination of the data, to establish a consistent disease 
course that could be separated into distinct segments. Statistical analysis was carried out by 
comparing the statistics between baseline (pre-infection), incubation (post-infection, pre-disease-
onset), febrile, and recovery periods.   
3.5.3 Analysis of Variance 
Analysis of variance was carried out to measure differences both within the same NHP as well as 
to determine differences between NHP subjects administered the same EEV but whose natural 
histories were differentiated by sick and well states. Repeated-measures ANOVA was run on each 
NHP subject, as data was collected continuously from each NHP. When analyzed at the 
standardized rate of one minute, the preponderance of samples from the data combined with the 
paucity of degrees of freedom between the days of the disease course resulted in ANOVA attaching 
significant differences in day-to-day variations in physiological measures at baseline when such 
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values were expected to lie within normal physiological parameters for a macaque. Therefore, a 
secondary standard rate of samples collected every 15 minutes was used for the repeated measures 
ANOVA. All significance levels utilized were α<0.05. 
3.5.4 Frequency Spectrum Analysis 
To examine changes in the circadian rhythm captured by electrocardiographic data, frequency 
spectrum analysis was carried out by use of the fast Fourier transform (FFT). Any periodic signal 
or waveform can be composed of a linear combination of basic trigonometric functions such as 
sine waves or cosines. Consider a function f(t), an irregularly shaped time series, with or without 
some obvious pattern, such as that in the example illustrated by Figure 8. For simplicity, consider  
 
 
                    Figure 8. Frequency Spectrum Analysis.  
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a known quantity of 5 sines or cosines, all functions of time. The FFT is applied, through the 
convolution integral (illustrated), and a discrete spectrum is produced, with each frequency point 
representing a component frequency of its respective trigonometric function. The y-axis represents 
the magnitude of the trigonometric function it represents, or how much of a role it plays in defining 
the original time-domain function. In this manner, subtle changes in the number of cycles per day, 
or the subcomponents of the normal cyclic rates of physiological or electrocardiographic 
parameters can be visualized and correlated with disease processes. These procedures were carried 
out in MATLAB with the use of native frequency analysis algorithms, modified for use with 
incomplete time series. Differences in frequency spectra were characterized by the absence or 
presence of peaks at various periods; the fundamental frequency, or the first defining frequency 
peak in the frequency spectrum window (delineated by ω1 in the example given above) was used 
pursuant to distinguishing the differences in pre-/post-infection, febrile, and recovery periods.  
3.5.5 Heart Rate Variation 
Due to the cardinal value of heart rate as a clinically relevant vital sign, variations in heart rate 
over days can point to shifts in physiological status. As stated previously, perturbations of HRV 
are associated with various pathological states. To characterize the heart rate variation, Poincare 
plots of daily HRV were generated by creating ordered pairs of a measured RR-Interval and the 
one immediately following it. The Poincare plots were then color-coded by pre-/post-infection, 
febrile, and recovery periods, and overlaid. This served to better visualize changes in HRV post-
infection and at baseline; the RR interval histograms were also plotted and overlaid for each 
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Poincare plot, and were compared through ANOVA. The method of constructing the histograms 
is as detailed in Brennan et al, and is detailed on the next page in Figure 9 [59]. 
 
 
Figure 9. HRV Poincare Plot Analysis.  
As mentioned previously, heart rate variability, as tracked by comparing an RR-interval measurement with its 
following RR-interval measurement, is prone to change as a function of autonomic homeostatic mechanisms and/or 
autonomic dysfunction. 
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4.0  RESULTS 
The analyses described were performed in rough triplicate for the three types of equine encephalitis 
viruses. Comparisons were also made between the disease profiles of the various EEVs. As the 
sheer number of ANOVA results and figures generated for the analyses are too voluminous to be 
concisely displayed in the results, some results are displayed in the appendix for the sake of 
manuscript brevity. 
4.1 ANALYSIS OF TELEMETRIC DATA 
4.1.1 Eastern Equine Encephalitis Virus 
4.1.1.1 Disease Course 
As far as delineating the courses of disease, infection with EEEV produced frank signs of disease 
in the form of fever and activity/neurological signs. Animals that received more than 1.1*108 PFU 
of EEEV died, whereas animals that received below this dose survived.  
In the animals that succumbed to infection, the disease course was replicated with high 
fidelity between both animals that did so. Post-challenge, the animals became febrile shortly after 
the 3-day mark, culminating in a febrile plateau of 40-41oC between days 4-5 post-infection. The 
fever plateau was followed by a decline in temperature at approximately 5.5 days post infection 
corresponding to a rapidly deteriorating state of health in the nonhuman primates as determined 
by both clinical score and the temperature profiles, the latter as detailed in Figure 10.  
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Figure 10. EEEV Disease Profiles.  
M160-16 and M162-16 displayed no signs of disease, while M161-16 and M163-16 manifested febrile illnesses and 
were considered lethally infected animals. 
 
In contrast, in the nonhuman primates that survived, M160-16 and M162-16, no 
manifestation of fever occurred, and no signs of encephalitides made themselves manifest in their 
behavior or activity. The animals appear to have emerged with no clinically apparent sequelae, 
either. Of note, one of the NHP subjects challenged with EEEV that survived the initial challenge 
was rechallenged, with the subsequent course illustrated in Figure 11, with the initial course plotted 
alongside for comparison. The results from the initial survey of the disease course  
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Figure 11. EEEV Post-Challenge Profiles of M160-16.  
 
 
Figure 12. EEEV Disease Course.  
This model holds for the NHPs sickened by EEEV; no signs of illness appear for up to three days; at three days, the 
onset of fever occurs and plateaus until the animal becomes moribund at ~5.5 days post infection. 
 
allowed for the construction of a model disease course for NHPs that succumbed to EEEV detailed 
in Figure 12. As per this model, the pre-infection period was defined as the period before the 
aerosol challenge, whereas the post-infection period is defined as the period following infection. 
For NHPs that did not progress to febrile illness (who did not show any overt signs of infection 
for the duration of their time courses), this constitutes the remainder of their data. However, for 
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NHPs that manifested febrile illness and encephalitis, the febrile period was consistently seen after 
three days post-infection, such that the post-infection and febrile periods in these NHPs were 
defined as 0-3 days post aerosol challenge, noninclusive, and 3-days post aerosol challenge, 
respectively. As neither of the sickened NHPs recovered, a recovery period was not applicable for 
definition in the case of Eastern Equine Encephalitis.   
4.1.1.2 Analysis of ECG Metrics 
The ECG metrics and their standard deviations (considered as ECG metrics in their own right) for 
which significant differences were found are summarized in Appendix A.1.  
ECG metrics were compared within each animal, due to the variability encountered in the 
baseline metrics collected for each NHP. Data obtained post-infection was compared to pre-
infection data for subjects M160-16 and M162-16 by t-tests upon satisfaction of the assumption 
of equal variances between data collected post-infection and that collected pre-infection, and one-
way ANOVAs were used to compare pre-infection, post-infection, and febrile period ECG data 
for NHPs M161-16 and M163-16. As M160-16 was challenged twice by aerosol, only data from 
the peri-challenge period of the first aerosol challenge was used. Repeated measures ANOVA 
tables can be found in the appendix. No significant differences were observed in any of the 
electrocardiography metrics for M160-16 and M162-16, the NHPs who survived the EEEV 
challenge by aerosol. Determination of infection status is subject to further analysis in pathology.  
 In NHPs challenged with EEEV, few to no arrhythmic beats (BAD) were detected 
throughout the recorded study, and no significant differences existed between the number of 
arrhythmic beats generated pre-/post-infection in any of the NHPs under study. The heart rate, 
however, exhibited differences between the NHPs that succumbed to infection versus those who 
did not; HR demonstrated a decrease in the post-infection period in M161-16 and peaked during 
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the febrile period, while the same metric demonstrated an increase in the post-infection period in 
M163-16 and also peaked during the febrile period. In both cases, the heart rate during the febrile 
period was increased by a factor of ~1.5x compared to baseline. The HR trends are illustrated en 
bloc in all NHPs in Figure 13, and a comparison between a nondiseased/diseased NHP by day is 
demonstrated in Figure 14.  
 
Figure 13. EEEV Heart Rate Profiles. 
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Figure 14. Heart Rate in EEEV-infected NHPs (daily).  
Units in (bpm). Red indicates significant differences by day; the amount of daily variability in average HR is evident 
through this figure. 
 
The PCt profiles of all 4 EEEV NHP subjects is displayed in Figure 15. The number of P-
waves counted in each sampling period (PCt) changed as well, in subjects M161-16 and M163-
16, as would be expected due to the increased heart rate. At a closer examination, however, this 
increase appears only to manifest at the end of the disease course, during the moribund stage of 
the febrile period. Though this difference distinguished the sickened NHPs from the NHPs that did 
not die from their illness, the number of P-waves documented in each sampling period 
demonstrated a persistent downward trend with a spike in P-wave count during terminal decline, 
when compared to M163-16, which demonstrated no change during the post-infection period but 
an increase during the fever, documented in Figure 16. 
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Figure 15. EEEV P-Wave Count Profiles. 
 
Figure 16. EEEV P-Wave Count by Disease Period in Sickened NHPs. 
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 The PR-Interval appears to decrease following the onset of the febrile period in the 
sickened NHPs, as documented in Figure 17. However, between the sickened NHPs M161-16 and 
M163-16, it appears that the PR-I initially increased from baseline in the post-infection period, 
whereas a negligible effect occurred in the PR-I of M163-16 post-infection, only showing an 
overall decrease during the febrile period with a small spike in PR-I as the animal became 
moribund, illustrated in Figure 18. The PR-I metric exhibited the same paradoxical behavior 
between the sickened NHPs M161-16 and M163-16 as with the PCt metric.  
 
Figure 17. EEEV PR-Interval Profiles. 
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Figure 18. EEEV PR-Interval Changes in Sickened NHPs compared to baseline. 
 
The width of the P-wave, P-Width, decreases during the febrile period in the sickened 
NHPs; profiles of P-Width are plotted in Figure 19. No changes were detected by period in the 
NHPs that did not become ill. The P-Width appears to have dampened in M161-16 post-infection, 
although the average P-Width increased in the post-infection period before decreasing in the febrile 
period, as demonstrated in Figure 20. In M163-16, no significant change appears to have taken 
place in the post-infection period, and the febrile period likewise saw a decrease in the P-wave 
width.  
The next metric to reveal significance was the QRS-interval; in this case, as documented 
by Figure 21 and Figure 22, QRS in both EEEV-sickened NHPs exhibited a progressive increase 
in the days following infection, through the febrile period. However, while the mean QRS in 
M161-16 increased by a factor of 1.16x, the mean QRS in M163-16 only increased 1.03x. 
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Figure 19. EEEV P-Width Profiles. 
 
Figure 20. EEEV P-Width Changes in Sickened NHPs. 
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Figure 21. EEEV QRS Profiles. 
 
Figure 22. EEEV QRS Changes in Sickened NHPs. 
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 The QT-interval data of the EEEV NHP subjects that succumbed to infection provided an 
interesting finding in that during the febrile period, the mean daily QT-I of both M161-16 and 
M163-16 decreased by factors of 1.25x and 1.24x, respectively, or to phrase it differently, reduced 
to 85% and 80% of their baseline values. No significant differences were detected in QT-I in the 
post-infection period, though for the following two days post-infection, there was an increase in 
the mean daily QT-I for both M161-16 and M163-16. Profiles of QT-I data against the disease 
course are demonstrated in Figure 23, while the mean daily QT-I profile is illustrated in Figure 24. 
M161-16 exhibited a great deal of noise in the QT-I signal, which required filtering, possibly 
leading to artifact generation, but the ANOVA data remains valid. 
 
Figure 23. EEEV QT-I Profiles. 
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Figure 24. EEEV Mean Daily QT-I in Sickened NHPs. 
  
Finally, the last metric for which significance was discovered was the RR-interval, which is 
reasonable given its collinearity with HR. The trend uncovered mirrored that of HR; RR-I in both 
M161-16 and M163-16 had decreased to 80% and 81% of baseline mean daily RR-I during the 
febrile period. RR-I profiles plotted against disease course are illustrated in Figure 25, and RR-I 
by period in the NHPs who succumbed to infection are displayed in Figure 26. 
The heart rate increase in the NHPs that succumbed to EEEV aerosol infection was the 
most consistent metric that accompanied the disease course; it stands to reason that the heart rate 
would increase as the animal becomes febrile, since altered homeostasis following the infection 
preceding and during the febrile period create a physiological milieu that favors immune cell 
chemotaxis to infected areas [60, 61]. The other significant metrics examined here  
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Figure 25. EEEV RR-I Profiles. 
 
Figure 26. EEEV Mean Daily RR-I in Sickened NHPs. 
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will covary with heart rate, as the compression of the entire ECG cycle relies on the compression 
of some or all of its constituent parts. In light of this information, it is unsurprising that PCt, P-
Width, and QT-I exhibit decreases by the end of the febrile period as well; what is surprising is 
the lengthening of the QRS interval during the febrile period. Examination of raw ECG trace 
obtained during the febrile period compared to the baseline ECG revealed no gross pathological 
signs, such as split or deformed QRS complexes (including R’ wave formation), of direct cardiac 
pathology such as a conduction / bundle branch block. As the QRS interval corresponds to 
ventricular depolarization in the heart, a widened QRS interval could point to electrolyte 
imbalances such as hypokalemia; as clinical observations noted, both M161-16 and M163-16 
exhibited decreased imbibition during their febrile periods, and also signs of dehydration. 
However, blood chemistry obtained at baseline, during aerosol, and at necropsy of M161-16 and 
M163-16 did not bear out this hypothesis, as potassium levels were within normal limits (3.5-5 
mEq).  
4.1.1.3 Frequency Spectrum Analyses 
The frequency spectrum analysis of the NHP subjects in EEEV present several interesting findings, 
the most exciting one of which lies in the observation that when subjected to the Fourier transform, 
pre-/post-infection and febrile periods are distinguishable in the NHP subjects that became ill by 
examining the fundamental frequency of each metric. The frequency spectra appear to vary little 
between ECG metrics, especially those that covary; for instance, metrics associated with HR, as 
discussed above, by and large exhibit similar trends, with few exceptions. In Figure 27, the four 
plots demonstrate the time-domain data (left) and frequency-domain (right) spectra of the RR-
Interval for M160-16, M161-16, M162-16, and M163-16. The amplitude of 
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Figure 27. EEEV RR-I Frequency Spectra. 
RR-Interval data plotted on the left, frequency spectra plotted on the right. From top to bottom: M160-16, M161-16, 
M162-16, M163-16. Blue for pre-infection, red for post-infection, and yellow for febrile period. 
 
 the frequency spectrum plots is not significant, as magnitude squared (ms2 in this case) is 
determined by the number of points fed into the Fourier Transform and also the value of time-
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domain function. The fundamental frequency, defined here as the first local maximum, represents 
the frequency with which the signal repeats, with all following peaks registering as harmonics, or 
echoes of the initial peak frequency. The trend seen in the EEEV NHPs that succumbed to infection 
was defined by an initial baseline frequency of 0.242 and 0.395 cycles per day (cpd) for M161-16 
and M163-16, respectively. Post-infection, this jumped to 0.769 and 0.879 cpd, then decreased to 
0.549 and 0.579 cpd for M161-16 and M163-16, respectively. NHPs thar emained healthy had 
small changes in RR-I frequency post-infection, but not to the same degree seen in sick NHPs. 
These data are summarized in Table 4.  
 
Table 4. EEEV Frequency Analysis Results. 
NHP 
Fundamental 
Frequency 
(cpd) 
Post-Infection 
Frequency 
(cpd) 
Febrile Period 
Frequency 
(cpd) 
Differences  
(Pre-Post-Feb) 
(cpd) 
M160-16 0.351 0.242 N/A (-0.109) 
M161-16 0.395 0.879 0.571 (0.484, -0.308) 
M162-16 0.307 0.351 N/A (0.044) 
M163-16 0.242 0.769 0.549 (0.527, -0.220) 
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4.1.1.4 Heart Rate Variability 
Heart rate variability in NHPs exposed to EEEV was decreased during the febrile period in 
sickened NHPs relative to healthy NHPs, who manifested no such changes (Figure 28). 
 
Figure 28. EEEV HRV Poincare Plot Overlays. 
Poincare plots of HRV by day; cyan denotes the pre-infection period, black the post-infection period, and red the 
febrile period. Though trends are visible by inspection, these ultimately proved not to be significant. 
 
One way ANOVA (Table 6), demonstrated that although significant differences exist between 
daily HRV plots, these differences are not meaningful when compared both within the same NHP 
subject and between sick and healthy subjects, as demonstrated by a comparison of the pairwise 
tests of the probability distributions. 
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Table 5. EEEV HRV Probability Density one-way ANOVA Results. 
 
 
 
Figure 29. EEEV HRV pairwise comparisons of probability density in M162-16 and M163-16. 
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4.1.2 Western Equine Encephalitis Virus 
4.1.2.1 Disease Course 
Challenge of NHPs with Western Equine Encephalitis Virus produced few signs of disease in the 
majority (75%, n = 4) of NHPs challenged, within a week post-infection. All animals survived the 
aerosol challenge except for the NHP (M169-16).  
The disease course of M169-16 serves as the only record with which to model the disease. 
M169-16 became febrile shortly after the 2-day mark, that slowly progressed to a febrile peak of 
40.56oC at 4.5 days post-infection, which persisted for another 2.5 days before the combination of 
temperature, activity, and neurological scores invoked the humane endpoint. Febrile courses for 
NHPs M166-16, M167-16, M168-16, and M169-16 are plotted in Figure 30.   
 
Figure 30. WEEV Disease Profiles. 
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By temperature profile and clinical scoring, NHP subjects M166-16, M167-16, and M168-
17 remained healthy post-challenge, with no manifestation of fever, and few if any signs of 
encephalitis. M167-16 arrived at the RBL with a malfunctioning implant, such that most data 
required censoring due to the unreliable accuracy of the data gathered. As such, M169-16 provided 
the only template for the construction of a model disease course for fatal WEEV infection by 
aerosol route, with the model shown in Figure 32. 
 
 
Figure 31. WEEV Disease Course.  
 
As with the EEEV model, the pre-infection period for WEEV consists of the baseline period before 
the aerosol challenge. The post-infection period consists of the period of seven days following 
aerosol challenge for healthy NHPs, while the period between 0-2 dpi, noninclusive, is defined as 
the post-infection period in M169-16. The febrile period then, is defined as 2-7 days, inclusive. 
This model as of the time of this writing holds only for this one observed subject. As the sickened 
NHP did not recover, no recovery period could be defined for Western Equine Encephalitis Virus.   
4.1.2.2 Analysis of ECG Metrics 
The ECG metrics and their standard deviations (considered as ECG metrics in their own right) for 
which significant differences were found are summarized in Appendix A.1.  
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Repeated measures ANOVA tables can be found in the appendix. Increased variability was 
found in the ECG metrics for the WEEV-exposed NHPs; therefore, follow-up t-tests and one way 
ANOVAs by day were required to assess whether or not true differences existed between the 
NHPs’ metrics. Due to the large number of significant variables, only the metrics in common with 
those significant in EEEV and VEEV NHPs will be discussed. 
 In NHPs challenged with WEEV, no significant differences developed in pre- and post-
infection period HR in M166-16 and M168-16, the NHPs that did not develop a febrile illness. In 
contrast, in M169-16, the HR was not affected during the post-infection period, but increased by 
a factor of 1.5x its initial value during the febrile period. The HR profiles are documented against 
the disease profiles in Figure 32.  Initially, repeated measures ANOVA had documented significant 
changes in the afebrile NHPs, but upon further analysis, it appears that baseline variability had 
triggered significance in the repeated measures analysis. The results of the change in HR for M169-
16 are plotted in Figure 32. 
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Figure 32. WEEV Heart Rate Profiles. 
Figure 33. Heart Rate in WEEV-sickened NHP. 
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No significant differences were detected in PCt for M166-16 and M168-16; however, it 
appears that as M169-16 entered the febrile period, its PCt increased by a factor of 1.5x, as would 
be expected from the HR data. These results can be seen in Figure 34 and 35, respectively.  
Figure 34. WEEV P-Wave Count Profiles. 
Figure 35. WEEV P-Wave Count by Disease Period in Sickened NHP. 
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The QRS data for WEEV are plotted against disease course in Figure 36. The QRS-interval 
in WEEV-infected NHPs exhibited a variety of behaviors; in M166-16 and M168-16, repeated 
measures ANOVA yielded significant results, which were then followed up by one way ANOVA 
of daily mean QRS-interval. The latter also yielded significant results, but post-hoc pairwise 
testing produced no significance. When compared by pre-infection and post-infection period, QRS 
in M166-16 decreases pre-infection to post-infection. In contrast, M168-16 exhibits an increase in 
QRS from pre-infection to post-infection. In M169-16, a much more marked effect was observed; 
on 2dpi, the QRS became reduced, eventually reaching 84% of its baseline value. To contrast the 
QRS profiles between fatal WEEV cases and afebrile cases, 
Figure 36. WEEV QRS Profiles. 
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Figure 37 demonstrates the relative lack of change in QRS in the afebrile NHPs as compared to 
M169-16, who succumbed to the infection.  
Figure 37. WEEV QRS Changes (Mean Daily QRS-I). 
The QT-interval data of the WEEV NHP subjects recapitulates an interesting trend also 
visible in the QR-interval data (not significant); it demonstrates, in M169-16, the complete 
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suppression, or shortening of the QT-I during the febrile period, a characteristic not immediately 
visible in the afebrile NHPs M166-16 and M168-16. These data can be visualized in Figure 38. 
However, the repeated measures ANOVA and subsequent one way ANOVA also demonstrated 
significance for M166-16 and M168-16, similar to the QRS-I data. Again, pairwise comparisons 
of pre-infection vs. post-infection data demonstrated differences, but mean daily QRS-I pairwise 
comparisons again downplays the meaningfulness of the statistical significance of the afebrile 
NHPs’ QRS-I data. Whereas the QT-I of M169-16 diminished to 81% of its baseline value, that 
of M166-16 reduced to only 95% of the baseline value. The significance for M168-16 can be traced 
to an artifact that stems from missing data. Pairwise comparisons can be seen in Figure 39.   
Figure 38. WEEV QT-I Profiles. 
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Figure 39. WEEV QT-I Changes (Mean Daily QT-I). 
 
Finally, the last common metric for which significance was discovered was the RR-
interval. The trend uncovered again mirrored that of HR; the data is plotted against disease course 
in Figure 40. The RR-I did not change to a significant degree in M166-16 nor M168-16; by 
contrast, by 2dpi, RR-I in M169-16 had decreased to 60% of baseline mean daily RR-I during the 
febrile period compared to 88% and 100% for M166-168-16, respectively. RR-I for M169-16  
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Figure 40. WEEV RR-I Profiles. 
is plotted in Figure 41, as mean daily RR-I. 
The findings for WEEV were remarkable in that the relevant ECG metrics here discussed 
only exhibited significant change after the onset of the febrile period. More variation in the baseline 
data, compounded by data loss, of the set of NHPs exposed to WEEV was experienced, leading to 
artifact generation in the results. In the case of M169-16, QRS-I appears to have decreased; the 
implications of this finding are unclear, though the literature points to this as a component of a 
poor prognosis, especially in the context of increased QRS-wave amplitude, which, though not 
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discussed, displayed significance in M169-16 [62]. The etiology behind the association with 
sudden death refers mainly to cardiogenic origins; however, recent investigation 
 
Figure 41. WEEV Mean Daily RR-I in Sickened NHPs. 
 
has suggested that autonomic modulation of sympathetic/parasympathetic predominance of heart 
rate regulation can lead to morphological changes in the QRS-interval, with a narrower QRS-I 
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representing a shift towards sympathetic predominance [63]. The increase in QRS-amplitude, 
however, does not manifest until during the febrile period; QRSA data are plotted against disease 
progression in Figure 42. 
 
 Figure 42. WEEV QRSA Profiles. 
4.1.2.3 Frequency Spectrum Analyses 
Frequency analysis of WEEV yields differences between fundamental frequencies that 
distinguish pre-/post-infection and febrile periods from each other. The frequency spectra again 
do not vary between covarying ECG metrics, and as such, RR-I was chosen as a representative 
sample of the frequency spectra of the WEEV-infected monkeys, shown in Figure 43.  
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Figure 43. WEEV RR-I Frequency Spectra. 
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RR-Interval data plotted on the left, frequency spectra plotted on the right. From top to bottom: M166-16, M167-16, 
M168-16, M169-16. Blue for pre-infection, red for post-infection, and yellow for febrile period. 
In the monkey that became ill, the fundamental frequency shifted to the right, then to the 
left as the febrile period approached; this stands in contrast to the fundamental frequencies 
observed for M166-16 and M168-16; though the post-infection period was defined by a shift of 
the fundamental frequency to a smaller frequency, variability between subjects was significant to 
the point that the magnitude of the change of fundamental frequency in M166-16 was twice that 
of M168-16. The fundamental frequencies of the WEEV frequency spectra data are summarized 
in Table 6.  
 
Table 6. WEEV Frequency Analysis Results. 
NHP 
Fundamental 
Frequency 
(cpd) 
Post-Infection 
Frequency 
(cpd) 
Febrile Period 
Frequency 
(cpd) 
Differences  
(Pre-Post-Feb) 
(cpd) 
M166-16 0.748 0.220 N/A (-0.528) 
M168-16 0.483 0.264 N/A (-0.219) 
M169-16 0.791 1.537 0.439 (0.746, -1.098) 
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4.1.2.4 Heart Rate Variability 
In the NHPs exposed to WEEV, HRV demonstrated a decrease during the febrile period in M169-
16; the healthy NHPs manifested changes in HRV, but as the variability of the data for 
 
Figure 44. WEEV HRV Poincare Plot Overlays. 
Poincare plots of HRV by day; cyan: pre-infection period, black: post-infection period, and red: febrile period.  
 
M166-16 and M168-16 demonstrate no peaks comparable to the downshift observable in the HRV 
data of M169-16. These are plotted in Figure 44. One way ANOVA, in Table 7, demonstrated 
significant differences in daily HRV plots, such that the febrile period HRV data is distinguishable 
from post-infection and pre-infection period HRV.  
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Table 7. WEEV HRV Probability Density one-way ANOVA Results. 
 
 
Figure 45. WEEV HRV post-hoc pairwise comparisons of probability density. 
 72 
4.1.3 Venezuelan Equine Encephalitis Virus 
4.1.3.1 Disease Course 
The disease course in Venezuelan Equine Encephalitis Virus produced a very characteristic 
bimodal fever profile in the NHPs infected; none of the NHPs challenged with VEEV died from 
the disease, and all recovered from their fevers. Unlike the EEEV and WEEV cohort of NHPs, 
which were all-male and all-female, respectively, the VEEV NHP cohort was mixed-sex. 
Post-challenge, the animals became febrile shortly at the 1dpi mark, with an initial fever 
peaking of 40-41oC at approximately 1.3dpi, followed by a return to normal temperature range by 
1.5dpi. A day later, at approximately 2.5dpi came the onset of a second fever, lasting four days 
until approximately 6.5dpi to 7dpi. The disease profiles are as detailed in Figure 46 and  
 
Figure 46. VEEV Disease Profiles. 
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modeled in Figure 47. Thus, four periods were initialized for analysis: pre-infection, post-
infection, febrile period, and recovery period. VEEV is unique in this work due to the fact that all 
subjects experienced the same disease profile.  
 
 
Figure 47. VEEV Disease Course.  
 
Although the disease courses of the NHPs in this cohort fit the same archetype, some 
idiosyncrasies existed in individual NHP subjects. For instance, though M164-16 did not reach an 
initial fever as defined by baseline temperature by the 1dpi mark, a temperature elevation occurred 
which fit the pattern of the initial febrile peaks of the other NHPs in the cohort. The disease course 
of M165 was marred by a bout of hypothermia beginning at the recovery period, wherein the 
NHP’s core temperature dropped below baseline.  
Analysis by repeated measures ANOVA found nothing of significance in any and all 
metrics, follow-up one way ANOVAs were performed to analyze for differences between periods. 
The ECG metrics and their standard deviations (considered as ECG metrics in their own right) for 
which significant differences were found are summarized in Appendix A.1.  
Data for each VEEV NHP subject was analyzed by one way ANOVA to compare pre-
infection, post-infection, febrile period, and recovery ECG data for NHPs M164-16 and M165-16, 
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M170-16, and M171-16. As nearly every metric yielded significance when analyzed thus, only the 
metrics in common with EEEV and WEEV will be discussed in this segment. One way ANOVA 
tables can be found in the appendix.    
Heart rate increased in all NHPs infected with VEEV from baseline, an effect that persisted 
through the biphasic febrile period through the recovery period. Heart rate data are plotted against 
disease profiles in Figure 48.  As testament to the speed with which the febrile peak occurred, the 
heart rate was found to be significantly elevated by factors of 1.1x to 1.2x compared to baseline, 
depending upon the NHP, and peaked at a factor of approximately 1.3x baseline in all NHPs during 
the febrile period. Heart rate comparison by period is displayed in Figure 49. Although the heart 
rate reached an even higher period average for M165-16, this may have had to do with her episode 
of hypothermia, for which she received daily heat-lamp warming; this may have produced an effect 
on the heart rate. It should also be noted that the female NHPs (M164-16 and M165-16) exhibited 
higher baseline heart rates than the males, though this could be correlated to body size and not sex. 
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Figure 48. VEEV Heart Rate Profiles. 
 
 
Figure 49. Heart Rate in VEEV-infected NHPs (period). 
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The QRS-interval in the VEEV infected NHPs against their disease courses are 
documented in Figure 50. An interesting effect observed was that by the recovery period, the QRS 
for the female NHPs were now higher than baseline, whereas the QRS for the male NHPs were 
decreased. These represented increases to 102% and 110% of baseline QRS for M164-16 and 
M165-16 respectively, and decreases to 95% for both M170-16 and M171-16, respectively. 
Differences by period can be seen in Figure 51.  
 
Figure 50. VEEV QRS Profiles. 
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Figure 51. VEEV QRS Changes in Sickened NHPs. 
 
When the amplitudes of the QRS intervals were examined (plotted in Figure 52), it was 
revealed that the QRSA for M164-16 and M165-16 decreased sharply during the post-infection 
period, and remained at a lower point than baseline through the febrile period and into recovery. 
The trend differed for QRSA in males M170-16 and M171-16, as the QRSA increased sharply 
during the post-infection period, decreased sharply during the febrile period, and increased during 
the recovery period, in the case of M171-16 returning to baseline, while M170-16’s QRSA was 
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elevated above baseline to 105% of baseline values. Differences in QRSA by period are plotted in 
Figure 53. Of note is that M164-16, M165-16, M170-16, and M171-16 received progressively 
lower doses of virus; thus, not only could body weight and sex be correlates/confounders of such 
results, but the lowest dose received by M171-16 could have resulted in a faster physiologic 
recovery from disease. The fact that M171-16 had the fewest observable signs/symptoms of VEEV 
illness supports this.  
 
 
Figure 52. VEEV QRSA Profiles. 
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Figure 53. VEEV QRSA Changes in Sickened NHPs. 
 
As the standard deviations for QRSA (QRSASD) were also significant, these trends were 
examined against the disease course (Figure 54); it appears that for female NHPs M164-16 and 
M165-16, the variability in QRS amplitude decreased following infection, and remained low; 
while the same trends in QRSASD appeared in M170-16 and M171-16, the results for M171-16 
were not statistically significant, possibly due to a dose-dependent factor. Differences in QRSASD 
by period are plotted in Figure 55. 
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Figure 54. VEEV QRSASD Profiles. 
Figure 55. VEEV QRSASD Changes in Sickened NHPs. 
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Examination of the QT-interval data of VEEV infected NHPs demonstrated that, with the 
sole exception of M170-16, the QT-I decreased during the post-infection period, and remained 
decreased during the febrile period. In M165-16 and M171-16, the QT-I remained decreased 
during the recovery period, but for M164-16, the QT-I returned to baseline. In M171-16, the QT-
interval manifested a consistent increase after the infection, through the febrile period and 
recovery. This can perhaps be explained by the fact that out of the four VEEV-infected NHPs, 
M170-16 had the lowest baseline QT-I; post-infection, one can visually inspect the QT-I data to 
determine that the range of QT-I values diminishes post-infection – the values decrease during the 
febrile period, then increase. QT-I is plotted over disease course in Figure 56, and differences in 
QT-I by period can be seen in Figure 57. 
Figure 56. VEEV QT-I Profiles. 
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Figure 57. VEEV QT-I Changes in Sickened NHPs. 
The RR-I decreased in all NHPs infected with VEEV post-infection, and remained 
persistently low through the recovery period. As expected, the trend in RR-I mirrors that of HR. 
The RR-I is plotted over disease courses in Figure 58, and differences by period in RR-I are plotted 
in Figure 59. 
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Figure 58. VEEV RR-I Profiles. 
Figure 59. EEEV Mean Daily RR-I in Sickened NHPs. 
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The cohort of VEEV NHPs had no fatalities. The disease course was defined by a number 
of ECG metrics that became elevated/decreased and persisted even after the febrile illness had 
subsided. Whether or not this persistence, such as in the case of HR and related metrics, is 
reflective of a physiologic milieu favoring chemotaxis to infected areas, or else is indicative of 
persistent autonomic dysfunction remains to be seen [60, 61]. The latter case is supported by 
clinical scores for M164-16 and M165-16 that do not return to baseline values until 13-14dpi.  The 
dichotomy in the behavior of the QRS interval reflects a dichotomy between several possible 
confounders: female/male sex, small/large body weight, and dose of VEEV received. Some 
literature demonstrates that menstrual cycles can precipitate effects on autonomic regulation that 
can manifest in ECG signal pattern disruption, though the focus of the study rested on HR and 
HRV [64]. From the ECG data alone it is impossible to determine conclusively the basis of the 
difference in the lengthening of the QRS interval during the febrile period. Examination of raw 
ECG trace obtained during the febrile period compared to the baseline ECG revealed no gross 
pathological signs, such as split or deformed QRS intervals, of direct cardiac pathology.  
4.1.3.2 Frequency Spectrum Analyses 
The frequency spectrum analysis of the NHP subjects in VEEV presents the finding that all periods 
discussed: pre-infection, post-infection, febrile, and recovery, can be distinguished in all NHPs in 
the VEEV cohort. Again, since covarying metrics displayed the same trends in the frequency 
spectra, only the RR-I plots will be displayed, as a representative sample in Figure 60.  
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Figure 60. VEEV RR-I Frequency Spectra. 
RR-Interval data plotted on the left, frequency spectra plotted on the right. From top to bottom: M164-16, M165-16, 
M170-16, M171-16. Blue: pre-infection, red: post-infection, yellow: febrile period, violet: recovery period. 
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As the cohort of NHPs displayed relatively similar disease profiles, the frequency analysis 
reflected this, and Table 8 lists the means of the fundamental frequencies, substratified by sex. The 
fundamental frequencies identified through the same method applied to the EEEV and WEEV 
cohorts yielded relatively high cyclic rates in the VEEV cohort, though the baseline values 
identified: 5.974 cpd and 11.245 cpd for female and male monkeys, represent the 17th and 32nd 
harmonics of an initial cyclic rate of 0.351 cpd, a value similar to the baseline values of EEEV 
frequency analysis. This points to the potential need for some kind of normalizing when comparing 
virus to virus. Values in parentheses are normalized to the first harmonic value. 
 
Table 8. VEEV Frequency Analysis Results. 
NHP 
Fundamental 
Frequency 
(cpd) 
Post-Infection 
Frequency 
(cpd) 
Febrile Period 
Frequency 
(cpd) 
Recovery Period 
Frequency  
(cpd) 
Differences  
(Pre-Post-Feb-Rec) 
(cpd) 
All 8.610 12.344 4.612 3.339 (3.734, -7.732, -1.273) 
Male 11.245 (0.351) 13.793 (0.431) 4.744 (0.148) 3.163 (0.099) 
(2.548, -9.049, -1.581) 
<0.080, -0.283, -0.049> 
Female 5.974 (0.373) 10.894 (0.681) 4.481 (0.281) 3.514 (0.220) 
(4.920, -6.413, -0.967) 
<0.080, -0.283, -0.049> 
M164-16 5.974 (0.373) 11.070 (0.692) 4.393 (0.275) 3.514 (0.220) 
(4.920, -6.413, -0.967) 
<0.319, -0.417, -0.055> 
M165-16 5.974 (0.373) 10.718 (0.670) 4.568 (0.286) 3.514 (0.220) 
(4.920, -6.413, -0.967) 
<0.297, -0.384, -0.066> 
M170-16 11.245 (0.351) 13.881 (0.434) 4.217 (0.132) 3.163 (0.099) 
(2.548, -9.049, -1.581) 
<0.083, -0.302, -0.033> 
M171-16 11.245 (0.351) 13.705 (0.428) 5.271 (0.165) 3.163 (0.099) 
(2.548, -9.049, -1.581) 
<0.077, -0.263, -0.066> 
 87 
4.1.3.3 Heart Rate Variability 
 
Figure 61. VEEV HRV Poincare Plot Overlays. 
Poincare plots of HRV by day; cyan denotes the pre-infection period, black the post-infection period, red the febrile 
period, and yellow the recovery period.  
 
HRV in VEEV-exposed NHPs downshifted in the post-infection period, which persisted through 
the recovery period; these profiles can be seen plotted in Figure 61. Although one way ANOVA 
demonstrated that these differences were significant, pairwise comparisons of the probability 
density functions composing the histograms of daily HRV distributions were not significantly 
different, and can be seen in Table 9; Figure 62 further illustrates these differences. 
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Table 9. VEEV HRV Probability Density one-way ANOVA Results. 
 
 
Figure 62. VEEV HRV post-hoc pairwise comparisons of probability density.  
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5.0  DISCUSSION 
5.1 COMPARISONS BETWEEN EQUINE ENCEPHALITIS VIRUSES 
The set of significant metrics shared between EEEV, WEEV, and VEEV consist of HR, PCt, PR-
I, QRS, QRSA, QT-I, and RR-I.  For those metrics in common, trends do not seem to manifest 
until febrile periods have been reached, with the exception of the QRS-interval. In EEEV, the 
QRS-interval widens, while in WEEV, the QRS-interval decreases. Though QRS-I exhibited 
consistent increases in NHPs sickened by EEEV, the results in WEEV were more inconsistent; 
however, when comparing QRS-I between fatal cases, the one fatal case of WEEV resulted in a 
reduced QRS-I. Globally, increases in mean daily metrics in diseased animals never exceeded 
approximately 1.5x baseline values, whereas decreased mean daily metrics in diseased animals 
never fell below 0.5x of baseline values, indicating potential thresholds for detection of anomalous 
patterns. 
Frequency spectrum analysis reveals similar trends in different periods of disease course; 
post-infection, the fundamental frequency increases, then decreases post-infection, and remains 
relatively unchanged in individuals who do not present with signs of disease. In contrast, disease-
free individuals often presented with little to no change in the fundamental frequencies post-
challenge. Interestingly, the fact that fundamental frequency is shifted in sublethally infected 
NHPs is also relevant, as it can provide insight into whether or not an individual was recently 
infected, in concordance with a supporting clinical diagnosis. Heart rate variability, in the context 
of all three viruses, downshifted to lower RR-In-RR-In+1 ordered pairs over the course of the 
disease; that is, as the disease progressed into the febrile period, the RR-intervals grew more 
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regular and also decreased, reflecting an increased heart rate during the febrile period. For EEEV 
and WEEV, day-to-day variations did not become readily apparent until the febrile period. 
However, for VEEV, an immediate shift of HRV occurred in the post-infection period and 
remained at a lower daily mean HRV which persisted into the recovery period.  
5.2 CORRELATION OF TELEMETRIC READS TO DISEASE PATHOGENESIS 
5.2.1 Determination of Core ECG Parameters 
The metrics found to vary consistently post-infection for all EEVs comprise a core set of 
electrocardiography parameters that can be used to track and define disease progression. This set 
includes HR, PCt, P-Width, PR-I, QRS, QRSA, QT-I, R-H, RR-I, and ST-I. Although the metrics 
included in this set provide limited specificity to any single virus, they are very useful when 
establishing that an animal has been infected leading to a lethal infection, correlating with fever 
and possibly providing an additional basis for measuring encephalitic disease.   
QRS appears to be a distinguishing variable whose effects are specific to each virus, though 
this remains to be tested. Examination of the VEEV data raises the question of whether or not the 
QRS-response was sex-specific. Male NHPs infected with VEEV exhibited a narrowed QRS 
interval while female NHPs infected with VEEV exhibited a widened QRS. However, with EEV 
the all-male cohort of NHPs exhibited widened QRS-interval in sick individuals, while the all-
female cohort of WEEV-exposed NHPs exhibited a narrowed QRS-interval in the sick individual, 
though the difference could be virus-specific. Taken together, the core set of ECG metrics 
amenable to the tracking of disease include a number of covariant metrics based on heart rate and 
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its components, and the ECG amplitude of the R-Wave. Raw ECG traces were not assessed to a 
significant degree, and the small sample size of the NHP cohorts would have hindered 
generalizability. 
5.2.2 Distinguishing Features of Equine Encephalitis Virus Disease Courses 
A specific aim of this work sought to establish a basis of comparison within each virus challenge 
cohort and if possible, between viruses. As discussed previously, QRS-interval provided 
information specific to each virus, a unique feature among core metrics established. Over the 
course of the work, it became evident that frequency spectrum analysis of the core metrics provides 
a more powerful delineator and marker of clinical disease state/period. The fundamental frequency 
of the waveform presented by the Fourier transforms of the core metrics’ time-domain data in each 
virus increased post-infection, then decreased during the onset of febrile illness. In the VEEV 
cohort, wherein a recovery period existed, the fundamental frequency proceeded to decrease again.  
5.3 EVALUATION OF ELECTROCARDIOGRAPHY MODALITY AS A 
MODALITY OF TELEMETRIC SURVEILLANCE IN A NONHUMAN PRIMATE 
MODEL OF ALPHAVIRUS BY AEROSOL ROUTE 
5.3.1 Use of Radiofrequency Electrocardiography for the Study of Disease Progression 
The use of ECG telemetry in conjunction with traditional methods of observation of animal 
subjects for natural history studies provides a wealth of valuable information because animals 
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cannot be directly observed on a continuous basis. This modality allows for indirect monitoring of 
physiological status when lab staff are unavailable and can potentially prognosticate the onset of 
disease or moribund state in an animal. Not only does this aid decision-making regarding humane 
endpoints for such investigations, but the use of telemetry has the potential to provide more specific 
indicators as to which virus an animal is infected with, something a nonspecific indicator such as 
temperature cannot do.   
Limitations of this work include the inability to investigate the electrocardiographic 
implications of the dose response relationship due to the small sample size of individual NHP 
subjects, and the inability to investigate differences in electrocardiography to a fine degree 
between NHPs who survived versus those who succumbed to aerosol EEV infection due to the 
variability between baseline parameters between subjects. Although relative changes from baseline 
within the same NHP could provide insight into disease course, as much of the data suggests 
marked deviations from baseline during illness, larger sample sizes are required to make a 
definitive judgment regarding the use of ECG telemetry in this manner. Likewise, the effects of 
the sex of the NHP upon the disease course also could not be investigated due to the small sample 
size of NHP subjects, and the relatively short course for which the disease was followed in them. 
With regard to ECG metrics, mean daily values do not appear to be the most robust unit of data to 
prognosticate disease, as metrics assessed in this manner give no indication of disease prior to the 
onset of clinically observable signs, with the notable exception of QRS intervals in the cohorts 
described.  
The beauty of using frequency spectrum analysis is that it could provide for the 
identification of disease in the context of a known disease course. If an individual is being 
monitored continuously over a long period of time, samples of electrocardiography data can be 
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taken from the individual, and in this work, provided the clearest demarcation of the period of 
disease course. The limitation inherent in this method of prognostication lies in the fact that there 
exists a need for a lead-time such that the analysis can be conducted over a period of hours or days; 
in this work, variations in circadian rhythm were analyzed with a sampling frequency of minutes, 
to look at circadian variation; these trends may not hold for analyses in shorter time windows, 
perhaps limiting clinical applicability. Direct translation, however, would find better applicability 
in real-time analysis such that determinations to treat illness could be made. However, just as 
Holter monitors can detect cardiac arrhythmias in human patients in real time, ECG telemetry can 
perhaps become clinically relevant in the realm of infectious disease as well.  
The same holds for the heart rate variability, but with one caveat – a method that went 
untested in this work was the use of different definitions of heart rate variability. While each RR-
I measure was compared to the one immediately preceding it, one wonders how much the results 
would have differed should each ordered pair have consisted of (RR-In, RR-In+5) or (RR-In, RR-
In+12), or any variant of such pairings. This could have identified more visually and statistically 
distinguishing differences between the variability data. 
Although a large portion of the raw ECG traces went uninspected, no frank signs of direct 
cardiac pathology were observable from the raw ECG traces examined (data not shown). The 
findings of this work thus lend credence to the notion that changes in the autonomic nervous system 
as a response to infection, with or without immune system involvement, can mediate changes 
observable by electrocardiographic monitoring. Unpublished pathology data from the larger 
overarching NHP alphavirus study has demonstrated that the virus spreads diffusely into all areas 
of the brain, resulting in granulocytic infiltration and vasculitides in the brain, perhaps contributory 
to the development and manifestation of neurological signs and encephalitis. As the hypothalamus 
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is not excluded from the viral onslaught, it remains conceivable that changes in sympathetic and 
parasympathetic tone can modulate ECG metrics.  
Questions that remain to be answered are as follows: Do sex-based differences in 
electrocardiographic signatures precipitate any effects on the response to infection by aerosol 
route, and if so, how does the periodicity of hormonal changes interfere or otherwise modify the 
outcome? Perhaps body weight, or animal size may exert an effect on the electrocardiographic 
trace not only in baseline data, but also in the post-infection period, through febrile illness. Finally, 
it may be helpful to determine whether or not a dose-dependent relationship exists between the 
manifestation of electrocardiographic changes and the dose of virus received, or even between 
electrocardiographic changes and the immune response observed.  
5.3.2 Recommendations for Future Use and Analysis of ECG Data 
Because there are problems with cross-reactivity among alphaviruses and possible interference 
between vaccines [13], evaluating vaccine candidates for efficacy would be easiest if the same 
NHP model were used for all 3 viruses. Thus, a set of recommendations for future work may 
improve the ability of the use of ECG data to help provide specific profiles and prognosticators of 
disease in the same animal when infected with different viruses.  
 As discussed previously, the majority of the metrics identified as a core set of 
electrocardiography metrics covary with each other. Dimension reduction can be carried out 
among covarying metrics for the purposes of principal component analysis. This could provide a 
more robust form of prognostication. 
 Another suggestion lies in the further implementation and standardization of normalization 
to the frequency spectrum analyses to occur as close to real time as possible. In this work, changes 
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in fundamental frequency were characterized by taking the difference in cycles per day from one 
period to another, whereas multiplicative methods of comparing frequency measures to baseline 
frequency measures may be more useful. The former additive/subtractive method does take into 
account the time-dependent nature of disease progression however, and differencing in this 
manner, albeit on a basis closer to real time may prove to be more effective in characterizing or 
prognosticating disease states before their onset.  
Finally, for HRV, a goal to work towards would be as discussed previously: to analyze 
different series of ordered pairs for HRV. The construction of a 3D scatterplot as opposed to 
overlaid 2D scatterplots, such that a vector (as in principal component analysis) can be constructed 
in 3D space that can point to whether or not HRV, or in which direction, is changing on a daily (or 
more frequent) basis.  
5.4 STATEMENT OF PUBLIC HEALTH SIGNIFICANCE: BIOSECURITY AND 
CLINICAL SURVEILLANCE OF INFECTIOUS DISEASE 
A significant public health imperative that drives the study of EEVs lies in the potential of EEVs 
to be weaponized and to investigate the course and mitigation of natural illness as well. The 
production of EEV aerosols for the purposes of bioweapon deployment with modern technology 
has come within reach of well-funded non-state actors and is entirely within the means of the 
military-industrial complexes of post-industrial nation-states [65, 66]. Research and development 
of such bioweapons in the case of the first description have historical precedents [67]. It behooves 
clinicians and researchers to explore new methods of disease detection and disease 
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prognostication, not only to protect against biological weapons attacks, but also to improve the 
surveillance, detection, and prognostication of disease courses. 
5.4.1 Historical and Contemporary Concerns for Equine Encephalitis Viruses 
During the Cold War, the USA and the USSR both sponsored programs intended to investigate 
and develop EEVs as a tactical tool to induce nonlethal casualties such that a conventional 
attacking force might be compelled to commit time and resources to attend to downed combatants. 
Specifically, the US first identified aerosolized VEEV as an ideal agent, due to its low mortality, 
fast growth, low infectious dose, stability in aerosol form, and propensity for infection by 
inhalation; it then began a program to simultaneously generate offensive bioweapon stockpiles and 
a vaccine as a countermeasure. Much groundbreaking work on aerobiology and the associated 
agents came as a result of these programs. Discovery of the US programs by Soviet espionage led 
the USSR to respond by beginning a VEEV program of its own[68].  
Détente in the 1970s and the end of the Cold War saw international bans enacted on 
bioweapon production, and the decreasing probability of use of such weapons in conflicts between 
nation-states [68]. Likewise, the fact that international norms and espionage have made secrecy a 
requirement for bioweapons programs significantly reduces the deterrent value of offensive 
bioweapon stockpiles. However, several nation-states have since continued offensive bioweapon 
production in violation of international law, and the 21st Century has witnessed the emergence of 
powerful non-state actors who have become alarmingly adept at asymmetric warfare to the extent 
that fragile nation-states remain embattled with them in prolonged conflicts [66]. This 
development, coupled with the tendency of more powerful nation-states to achieve long-term 
geopolitical goals by surreptitiously collaborating with non-state actors such that the latter achieve 
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the former’s goals by proxy, create an environment conducive to the development, proliferation, 
and deployment of bioweapons as preemptive or vengeance strikes by both state- and non-state 
actors. 
 The United States faced a harrowing new set of challenges in the months and years 
following the September 11th 2001 attacks coupled with the Amerithrax B. anthracis spore attacks; 
these events underscored the need for effective contingency plans for ensuring national security in 
the face of widespread vulnerability to attack, culminating in the establishment of risk-stratified 
Category A, B, and C agent lists (in decreasing order of risk priority) by the CDC; the EEVs 
discussed rank in Category B [69]. The relatively low technical requirements and ease with which 
the EEVs may be manufactured, stored, and dispersed, combined with the difficulty of large-scale 
defense against such attacks, belie the EEVs’ Category B status; the very nature of the decreased 
infectiousness and virulence may make the application of EEV all the more attractive to those who 
seek to employ the pathogen for nefarious purposes [66, 70, 71].    
5.4.2 Surveillance, Detection, and Prognostication of Infectious Disease  
The foremost takeaway from this work, however, lies in the exploration of nontraditional methods 
of disease detection in the context of infectious disease. For a wide spectrum of infectious diseases 
spanning the pantheon of microbiological pathogens, clinicians are presented with an equally great 
array of information regarding the differential diagnosis of an afflicted individual upon 
presentation to the clinical setting. In the event of a large outbreak of an uncommon disease, the 
burden of a large influx of patients presenting with an unfamiliar set of symptoms can stretch a 
healthcare system beyond its capacity to effectively fulfill its mission of diagnosing and treating 
patients. The promise of studying alphaviruses in a well-defined animal model, not only in the 
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context of aerobiology for the sake of biosecurity, biodefense, lies also in the prospect of vaccine 
development and the establishment and improvement of better biotechnology that can achieve 
clinical applicability for both chronic and acute disease surveillance. As much work is currently 
underway to make feasible the use of blood tests that can identify viruses, the applications of the 
work described here can be used as a delimiter of whether or not to treat, and can be applied to 
prognostication of the severity of illness.  
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APPENDIX A: ANOVA TABLES 
A.1 SIGNIFICANT ECG METRICS FOR EQUINE ENCEPHALITIS VIRUSES 
Table 10. Repeated Measures ANOVA Summary for EEEV. 
Electrocardiography Metric NHP Metric Significance SD Significance 
BAD 
M160-16 ns ns 
M161-16 ns ns 
M162-16 ns ns 
M163-16 ns ns 
HR 
M160-16 ns ns 
M161-16 ** ns 
M162-16 ns ns 
M163-16 *** ns 
MxdV 
M160-16 ns ns 
M161-16 ns ns 
M162-16 ns ns 
M163-16 * ns 
Noise 
M160-16 ns ns 
M161-16 ns ns 
M162-16 ns ns 
M163-16 * ns 
 
PCt 
 
M160-16 ns ns 
M161-16 * ns 
M162-16 ns ns 
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Table 10 (cont’d)    
M163-16 *** ns 
P-H 
M160-16 * ns 
M161-16 * ns 
M162-16 ns ns 
M163-16 ns ns 
PR-I 
M160-16 ns ns 
M161-16 * ns 
M162-16 ns ns 
M163-16 ** ns 
P-Width 
M160-16 ns ns 
M161-16 * ns 
M162-16 ns ns 
M163-16 * ns 
QATN 
M160-16 * * 
M161-16 ns ns 
M162-16 ns ns 
M163-16 *** ns 
QR-I 
M160-16 ns ns 
M161-16 ns ns 
M162-16 ns ns 
M163-16 * ns 
QRS 
M160-16 ns ns 
M161-16 * ns 
M162-16 ns ns 
M163-16 * ns 
QRSA M160-16 ns ns 
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Table 10 (cont’d) M161-16 * ns 
M162-16 ns ns 
M163-16 * ns 
QT-I 
M160-16 * * 
M161-16 ns ns 
M162-16 ns ns 
M163-16 ****** ns 
R-H 
M160-16 ns ns 
M161-16 * ns 
M162-16 ns ns 
M163-16 ** ns 
RR-I 
M160-16 ns ns 
M161-16 * ns 
M162-16 ns ns 
M163-16 *** ns 
ST-E 
M160-16 ns * 
M161-16 * ns 
M162-16 ns ns 
M163-16 ***** ns 
ST-I 
M160-16 * * 
M161-16 ns ns 
M162-16 ns ns 
M163-16 ****** ns 
T-H 
M160-16 ns * 
M161-16 ns ns 
M162-16 ns ns 
M163-16 ns ns 
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Table 10 (cont’d)    
T-HN 
M160-16 ns ns 
M161-16 ns ns 
M162-16 ns ns 
M163-16 * ns 
T-P 
M160-16 ns ns 
M161-16 ns ns 
M162-16 ns ns 
M163-16 ns ns 
T-Pe 
M160-16 ns * 
M161-16 ns ns 
M162-16 ns ns 
M163-16 *** ns 
 
Table 11. Repeated Measures ANOVA Summary for WEEV. 
Electrocardiography Metric NHP Metric Significance SD Significance 
BAD 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
HR 
M166-16 ns ns 
M168-16 ns ns 
M169-16 *** ns 
MxdV 
M166-16 ns ns 
M168-16 ns ns 
M169-16 *** * 
Noise\ M166-16 ns ns 
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Table 11 (cont’d) M168-16 ns ns 
M169-16 ** ns 
PCt 
M166-16 * ns 
M168-16 ************ ns 
M169-16 *** ns 
P-H 
M166-16 ns ns 
M168-16 ns ns 
M169-16 * ns 
PR-I 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ** ns 
P-Width 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
QATN 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
QR-I 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns Ns 
QRS 
M166-16 * ns 
M168-16 ********************* ns 
M169-16 ** * 
QRSA 
M166-16 ns ns 
M168-16 ** ns 
M169-16 ** ** 
QT-I M166-16 ns ns 
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Table 11 (cont’d) M168-16 ns ns 
M169-16 ***** ns 
R-H 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
RR-I 
M166-16 ns ns 
M168-16 ns ns 
M169-16 *** ns 
ST-E 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
ST-I 
M166-16 *** ns 
M168-16 ********************* ns 
M169-16 ***** ns 
T-H 
M166-16 ns ns 
M168-16 ns ns 
M169-16 * ** 
T-HN 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
T-P 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
T-Pe 
M166-16 ns ns 
M168-16 ns ns 
M169-16 ns ns 
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Table 12. One Way ANOVA Summary for VEEV, by Period. 
Electrocardiography Metric NHP Metric Significance SD Significance 
BAD 
M164-16 ns ns 
M165-16 ns ns 
M170-16 ns ns 
M171-16 ns ns 
HR 
M164-16 *x31 ns 
M165-16 *x60 *x30 
M170-16 ********* *x36 
M171-16 *x64 ** 
MxdV 
M164-16 *x35 Ns 
M165-16 *x27 *x29 
M170-16 *x17 *x26 
M171-16 ********* ** 
Noise 
M164-16 ns ns 
M165-16 ns ns 
M170-16 ns ns 
M171-16 ns ns 
PCt 
M164-16 *x23 ns 
M165-16 *x45 ns 
M170-16 ********** ns 
M171-16 *x30 ns 
 
P-H 
 
M164-16 ns ** 
M165-16 ns ******* 
M170-16 *x22 ******** 
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Table 12 (cont’d) M171-16 ns *x36 
PR-I 
M164-16 *x67 * 
M165-16 ns **** 
M170-16 *x45 *x14 
M171-16 *x62 ******* 
P-Width 
M164-16 ******** * 
M165-16 *x22 ******* 
M170-16 * *x16 
M171-16 *x26 ******* 
QATN 
M164-16 *x38 *********** 
M165-16 *x88 *x24 
M170-16 *x37 ****** 
M171-16 *x92 *x62 
QR-I 
 
M164-16 ************ ns 
M165-16 *x28 ************ 
M170-16 *x24 *x23 
M171-16 *x26 **** 
QRS 
M164-16 *x18 ns 
M165-16 *x91 *x18 
M170-16 *x30 *x36 
M171-16 *x50 ***** 
QRSA 
M164-16 ************ * 
M165-16 *x61 *x26 
M170-16 *x23 *x40 
M171-16 *x30 **** 
 
QT-I 
M164-16 *x22 ******** 
M165-16 *x37 ** 
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Table 12 (cont’d) M170-16 **************** ns 
M171-16 *x49 ns 
R-H 
M164-16 *********** ** 
M165-16 *x59 *x26 
M170-16 *x26 *x43 
M171-16 *x30 **** 
RR-I 
M164-16 *x30 ns 
M165-16 *x96 *x82 
M170-16 ********** *x23 
M171-16 *x100 ** 
ST-E 
M164-16 *x34 ns 
M165-16 *x36 ********** 
M170-16 ******** *x46 
M171-16 *x35 *x10 
ST-I 
M164-16 *x22 ** 
M165-16 *x38 ********* 
M170-16 ******* * 
M171-16 *x48 * 
T-H 
M164-16 ns ns 
M165-16 *x39 **** 
M170-16 *x34 * 
M171-16 *x98 **** 
T-HN 
M164-16 ******* ns 
M165-16 ************* ******* 
M170-16 **** * 
M171-16 *x45 ns 
T-P M164-16 *x40 ns 
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Table 12 (cont’d) M165-16 *x73 **** 
M170-16 ***** * 
M171-16 *x49 * 
T-Pe 
M164-16 *x44 * 
M165-16 *x44 ******* 
M170-16 ******** ns 
M171-16 *x35 * 
 
A.2 EEEV ANOVA RESULTS 
Table 13. Repeated Measures ANOVA for EEEV HR. 
 
 
 
 
M163-16 HR 
rmANOVA 
M162-16 HR 
rmANOVA 
M161-16 HR 
rmANOVA 
M160-16 HR 
rmANOVA 
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Table 14. Repeated Measures ANOVA for EEEV PCt. 
 
Table 15. Repeated Measures ANOVA for EEEV PR-I. 
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Table 16. Repeated Measures ANOVA for EEEV P-Width. 
 
Table 17. Repeated Measures ANOVA for EEEV QRS. 
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Table 18. Repeated Measures ANOVA for EEEV QT-I. 
 
 
Table 19. Repeated Measures ANOVA for EEEV RR-I. 
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A.3 WEEV ANOVA RESULTS 
Table 20. Repeated Measures ANOVA and One Way ANOVA for WEEV HR. 
 
 
Table 21. Repeated Measures ANOVA and One Way ANOVA for WEEV PCt. 
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Table 22. Repeated Measures ANOVA and One Way ANOVA for WEEV QRS. 
 
 
Table 23. Repeated Measures ANOVA and One Way ANOVA for WEEV QT-I. 
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Table 24. Repeated Measures ANOVA and One Way ANOVA for WEEV RR-I. 
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A.4 VEEV ANOVA RESULTS 
Table 25. One Way ANOVA for VEEV HR. 
 
Table 26. One Way ANOVA for VEEV QRS. 
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Table 27. One Way ANOVA for VEEV QRSA. 
 
 
 
Table 28. One Way ANOVA for VEEV QRSASD. 
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Table 29. One Way ANOVA for VEEV QT-I. 
 
 
Table 30. One Way ANOVA for VEEV RR-I. 
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APPENDIX B: PERTINENT MATLAB CODE FOR ANALYSES 
Designation “M1XX-16_(M/F)_(E/W/V)_(L/D)_Var” used as a placeholder for a given NHP. 
B.1 DATA PROCESSING AND PROFILE GENERATON 
B.1.1 Data Processing and Filtration 
%% Temperature Profiles 
    %Temperature Profiles Plotted with Cumulative Fever Hours 
for i= 1:1 
figure(1); 
Htemp = gcf; 
hold on; 
  
    %M1xx  
  
        ii = 1; 
    while ii < length(M1XX-16_DPI')+1 
        if ((M1XX-16_(M/F)_(E/W/V)_(L/D)_T_Mean(ii,1))>42) || (M1XX-16_(M/F)_(E/W/V)_(L/D)_T_Mean(ii,1)<22)  
            M1XX-16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(ii,1) = NaN; 
        else  
            M1XX-16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(ii,1) = M1XX-16_(M/F)_(E/W/V)_(L/D)_T_Mean(ii,1); 
        end 
            ii= ii+1; 
    end 
    M1XX-16_ARIMA = [(mean(M1XX-16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(1:2881),'omitnan')-(2*std(M1XX-
16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(1:2881),'omitnan'))) (mean(M1XX-16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(1:2881),'omitnan')) (mean(M1XX-
16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(1:2881),'omitnan')+(2*std(M1XX-16_(M/F)_(E/W/V)_(L/D)_T_MeanCens(1:2881),'omitnan')))]; 
    
    subplot(n,m,p), 
        aero1 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
        hold; 
        title('M1XX-16'); 
        yyaxis left 
        pt1 = plot(M1XX-16_DPI, M1XX-16_(M/F)_(E/W/V)_(L/D)_T_MeanCens,'.b'); 
        xlim([-3 15]); 
        ylim([32 42]); 
        line([-6 30], [M1XX-16_ARIMA(1,1) M1XX-16_ARIMA(1,1)],'LineWidth',1);   
        line([-6 30], [M1XX-16_ARIMA(1,2) M1XX-16_ARIMA(1,2)],'LineWidth',0.5);   
        line([-6 30], [M1XX-16_ARIMA(1,3) M1XX-16_ARIMA(1,3)],'LineWidth',1);   
        xlabel ('DPI(d)'); 
        ylabel ('Temperature (^oC)','Color','b'); 
        yyaxis right 
        pc1 = plot(M1XX-16_DPI, M1XX-16_(M/F)_(E/W/V)_(L/D)_CumFH,'.r'); 
        ylim([0 100]); 
        ylabel ('Cumulative Fever-Hours(h)', 'Color','r'); 
        subplotobj = subplot(n,m,p,'Parent',Htemp); 
        set(subplotobj,'XColor',[0 0 0],'YColor',[1 0 0],'ZColor',[0 0 0]); 
end 
 
%% Clinical Scores 
%% Clinical Scores – Daily Clinical Score, scaled to temperature curve 
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for i=1:1 
    M1XX_Clin = [3 3 3 3 4 6 5 5 4 4 4 4 4 3 4 4 4 3 3]; 
       M1XXModClin = 32+(42-32).*(M1XX_Clin./100); 
end  
B.1.2 Profile Generation 
Case: Heart Rate, M166-16, M167-16, M168-16, M169-16 
Metric 
%HR - Heart Rate 
            for i=1:1 
            disp('HR-Run'); 
            SubtitleHR = {'M166-16', 'M167-16','M168-16','M169-16'}; 
            figure(5) 
            HHR = gcf;  
            hold on; 
             
            jj = 1; 
            while jj<5 
                switch jj 
                        case 1 
                            M166_F_W_L_HRCens = []; 
                            ii = 1;  
                            while ii < length(M166_DPI')+1 
                                 if (M166_F_W_L_HR(ii,1)>400) || (M166_F_W_L_HR(ii,1)<40)  
                                   M166_F_W_L_HRCens(ii,1) = M166_F_W_L_HR(ii-1,1); 
                                 else  
                                   M166_F_W_L_HRCens(ii,1) = M166_F_W_L_HR(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end                     
                            subplot(2,2,jj) 
                            hold; 
                            aero1 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHR(1,jj)); 
                            yyaxis left 
                            b1 = bar([-3 -2 -1 0 1 2 3 4 5 6 7], M166ModClin,'y'); 
                            hold on; 
                            M166ModCumFH = 32+(42-32).*(M166_F_W_L_CumFH./100); 
                            pc1 = plot(M166_DPI, M166ModCumFH,'.r'); 
                            hold on; 
                            pt1 = plot(M166_DPI, M166_F_W_L_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M166_ARIMA(1,1) M166_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M166_ARIMA(1,2) M166_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M166_ARIMA(1,3) M166_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr1= plot(M166_DPI, M166_F_W_L_HRCens,'.c'); 
                            ylim([0 400]); 
                            ylabel ('HR (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHR); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                        
                        case 2 
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                            M167_F_W_L_T_HRCens = []; 
                            ii = 1;  
                            while ii < length(M167_DPI')+1 
                                 if (M167_F_W_L_HR(ii,1)>400) || (M167_F_W_L_HR(ii,1)<40)  
                                   M167_F_W_L_HRCens(ii,1) = NaN; 
                                 else  
                                   M167_F_W_L_HRCens(ii,1) = M167_F_W_L_HR(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end    
                            subplot(2,2,jj) 
                            hold; 
                            aero2 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHR(1,jj)); 
                            yyaxis left 
                            b2 = bar([-3 -2 -1 0 1 2 3 4 5 6 7], M167ModClin,'y'); 
                            hold on; 
                            M167ModCumFH = 32+(42-32).*(M167_F_W_L_CumFH./100); 
                            pc2 = plot(M167_DPI, M167ModCumFH,'.r'); 
                            hold on; 
                            pt2 = plot(M167_DPI, M167_F_W_L_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M167_ARIMA(1,1) M167_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M167_ARIMA(1,2) M167_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M167_ARIMA(1,3) M167_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr2= plot(M167_DPI, M167_F_W_L_HRCens,'.c'); 
                            ylim([0 400]); 
                            ylabel ('HR (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHR); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                         
                        case 3 
                            M168_F_W_L_T_HRCens = []; 
                            ii = 1;  
                            while ii < length(M168_DPI')+1 
                                 if (M168_F_W_L_HR(ii,1)>400) || (M168_F_W_L_HR(ii,1)<40)  
                                   M168_F_W_L_HRCens(ii,1) = M168_F_W_L_HR(ii-1,1); 
                                 else  
                                   M168_F_W_L_HRCens(ii,1) = M168_F_W_L_HR(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end    
                             subplot(2,2,jj) 
                            hold; 
                            aero3 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHR(1,jj)); 
                            yyaxis left 
                            b3 =  bar([-3 -2 -1 0 1 2 3 4 5 6 7], M168ModClin,'y'); 
                            hold on; 
                            M168ModCumFH = 32+(42-32).*(M168_F_W_L_CumFH./100); 
                            pc3 = plot(M168_DPI, M168ModCumFH,'.r'); 
                            hold on; 
                            pt3 = plot(M168_DPI, M168_F_W_L_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M168_ARIMA(1,1) M168_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M168_ARIMA(1,2) M168_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M168_ARIMA(1,3) M168_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
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                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr3= plot(M168_DPI, M168_F_W_L_HRCens,'.c'); 
                            ylim([0 400]); 
                            ylabel ('HR (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHR); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                         
                        case 4 
                            M169_F_W_D_T_HRCens = []; 
                            ii = 1;  
                            while ii < length(M169_DPI')+1 
                                 if (M169_F_W_D_HR(ii,1)>400) || (M169_F_W_D_HR(ii,1)<40)  
                                   M169_F_W_D_HRCens(ii,1) = M169_F_W_D_HR(ii-1,1); 
                                 else  
                                   M169_F_W_D_HRCens(ii,1) = M169_F_W_D_HR(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end   
                             subplot(2,2,jj) 
                            hold; 
                            aero4 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHR(1,jj)); 
                            yyaxis left 
                            b4 =  bar([-3 -2 -1 0 1 2 3 4 5 6 7], M169ModClin,'y'); 
                            hold on; 
                             M169ModCumFH = 32+(42-32).*(M169_F_W_D_CumFH./100); 
                            pc3 = plot(M169_DPI, M169ModCumFH,'.r'); 
                            hold on; 
                            pt4 = plot(M169_DPI, M169_F_W_D_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M169_ARIMA(1,1) M169_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M169_ARIMA(1,2) M169_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M169_ARIMA(1,3) M169_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]);legend([pt1 pc1 phr1 b1 aero1], {'Temperature (^oC)', 'Cumulative Fever-Hours (h)', 'Heart Rate (bpm)', 'Clinical 
Score', 'Aerosol Challenge'}); %legend 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr4= plot(M169_DPI, M169_F_W_D_HRCens,'.c'); 
                            ylim([0 400]); 
                            ylabel ('HR (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHR); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                end          
                jj=jj+1; 
            end 
             
              mtit(HHR,'WEEV Heart Rate Profiles'); %overtitle 
           legend([pt1 pc1 phr1 b1 aero1], {'Temperature (^oC)', 'Cumulative Fever-Hours (h)', 'Heart Rate (bpm)', 'Clinical Score', 'Aerosol 
Challenge'}); %legend 
  
            disp('HR-done') 
            %%unfold             
            end 
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SD 
%HRSD - Heart Rate 
            for i=1:1 
            disp('HRSD-Run'); 
            SubtitleHRSD = {'M166-16', 'M167-16','M168-16','M169-16'}; 
            figure(28) 
            HHRSD = gcf;  
            hold on; 
             
            jj = 1; 
            while jj<5 
                switch jj 
                        case 1 
                            M166_F_W_L_HRSDCens = []; 
                            ii = 1;  
                            while ii < length(M166_DPI')+1 
                                 if (M166_F_W_L_HRSD(ii,1)>400) || (M166_F_W_L_HRSD(ii,1)<0)  
                                   M166_F_W_L_HRSDCens(ii,1) = M166_F_W_L_HRSD(ii-1,1); 
                                 else  
                                   M166_F_W_L_HRSDCens(ii,1) = M166_F_W_L_HRSD(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end                     
                            subplot(2,2,jj) 
                            hold; 
                            aero1 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHRSD(1,jj)); 
                            yyaxis left 
                             b1 = bar([-3 -2 -1 0 1 2 3 4 5 6 7], M166ModClin,'y'); 
                            hold on; 
                            M166ModCumFH = 32+(42-32).*(M166_F_W_L_CumFH./100); 
                            pc1 = plot(M166_DPI, M166ModCumFH,'.r'); 
                            hold on; 
                            pt1 = plot(M166_DPI, M166_F_W_L_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M166_ARIMA(1,1) M166_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M166_ARIMA(1,2) M166_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M166_ARIMA(1,3) M166_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr1= plot(M166_DPI, M166_F_W_L_HRSDCens,'.c'); 
                            ylim([0 50]); 
                            ylabel ('HRSD (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHRSD); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                        
                        case 2 
                            M167_F_W_L_T_HRSDCens = []; 
                            ii = 1;  
                            while ii < length(M167_DPI')+1 
                                 if (M167_F_W_L_HRSD(ii,1)>400) || (M167_F_W_L_HRSD(ii,1)<0)  
                                   M167_F_W_L_HRSDCens(ii,1) = M167_F_W_L_HRSD(ii-1,1); 
                                 else  
                                   M167_F_W_L_HRSDCens(ii,1) = M167_F_W_L_HRSD(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end    
                            subplot(2,2,jj) 
                            hold; 
                            aero2 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
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                            hold on; 
                            title(SubtitleHRSD(1,jj)); 
                            yyaxis left 
                              b2 = bar([-3 -2 -1 0 1 2 3 4 5 6 7], M167ModClin,'y'); 
                            hold on; 
                            M167ModCumFH = 32+(42-32).*(M167_F_W_L_CumFH./100); 
                            pc2 = plot(M167_DPI, M167ModCumFH,'.r'); 
                            hold on; 
                            pt2 = plot(M167_DPI, M167_F_W_L_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M167_ARIMA(1,1) M167_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M167_ARIMA(1,2) M167_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M167_ARIMA(1,3) M167_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr2= plot(M167_DPI, M167_F_W_L_HRSDCens,'.c'); 
                            ylim([0 50]); 
                            ylabel ('HRSD (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHRSD); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                         
                        case 3 
                            M168_F_W_L_T_HRSDCens = []; 
                            ii = 1;  
                            while ii < length(M168_DPI')+1 
                                 if (M168_F_W_L_HRSD(ii,1)>400) || (M168_F_W_L_HRSD(ii,1)<0)  
                                   M168_F_W_L_HRSDCens(ii,1) = M168_F_W_L_HRSD(ii-1,1); 
                                 else  
                                   M168_F_W_L_HRSDCens(ii,1) = M168_F_W_L_HRSD(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end    
                             subplot(2,2,jj) 
                            hold; 
                            aero3 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHRSD(1,jj)); 
                            yyaxis left 
                             M168ModCumFH = 32+(42-32).*(M168_F_W_L_CumFH./100); 
                            pc3 = plot(M168_DPI, M168ModCumFH,'.r'); 
                            hold on; 
                            pt3 = plot(M168_DPI, M168_F_W_L_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M168_ARIMA(1,1) M168_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M168_ARIMA(1,2) M168_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M168_ARIMA(1,3) M168_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr3= plot(M168_DPI, M168_F_W_L_HRSDCens,'.c'); 
                            ylim([0 50]); 
                            ylabel ('HRSD (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHRSD); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                         
                        case 4 
                            M169_F_W_D_T_HRSDCens = []; 
                            ii = 1;  
                            while ii < length(M169_DPI')+1 
                                 if (M169_F_W_D_HRSD(ii,1)>400) || (M169_F_W_D_HRSD(ii,1)<0)  
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                                   M169_F_W_D_HRSDCens(ii,1) = M169_F_W_D_HRSD(ii-1,1); 
                                 else  
                                   M169_F_W_D_HRSDCens(ii,1) = M169_F_W_D_HRSD(ii,1); 
                                 end 
                                     ii= ii+1; 
                            end   
                             subplot(2,2,jj) 
                            hold; 
                            aero4 = line([0 0], [-100 100],'LineWidth',2,'Color','m'); 
                            hold on; 
                            title(SubtitleHRSD(1,jj)); 
                            yyaxis left 
                             M169ModCumFH = 32+(42-32).*(M169_F_W_D_CumFH./100); 
                            pc3 = plot(M169_DPI, M169ModCumFH,'.r'); 
                            hold on; 
                            pt4 = plot(M169_DPI, M169_F_W_D_T_MeanCens,'.b'); 
                            hold on; 
                            line([-6 30], [M169_ARIMA(1,1) M169_ARIMA(1,1)],'LineWidth',1); 
                            hold on; 
                            line([-6 30], [M169_ARIMA(1,2) M169_ARIMA(1,2)],'LineWidth',0.5); 
                            hold on; 
                            line([-6 30], [M169_ARIMA(1,3) M169_ARIMA(1,3)],'LineWidth',1); 
                            hold on; 
                            xlim([-3 7]); 
                            ylim([32 42]); 
                            xlabel ('DPI(d)'); 
                            ylabel ('Temperature (^oC)','Color','b'); 
                            hold; 
                            yyaxis right 
                            phr4= plot(M169_DPI, M169_F_W_D_HRSDCens,'.c'); 
                            ylim([0 50]); 
                            ylabel ('HRSD (bpm)','Color','c'); 
                            hold; 
                            subplotobj = subplot(2,2,jj,'Parent',HHRSD); 
                        set(subplotobj,'XColor',[0 0 0],'YColor',[0 1 1],'ZColor',[0 0 0]); 
                end          
                jj=jj+1; 
            end 
             
              mtit(HHRSD,'WEEV Heart Rate SD Profiles'); %overtitle 
           legend([pt1 pc1 phr1 aero1], {'Temperature (^oC)', 'Cumulative Fever-Hours (h)', 'HR-SD (bpm)', 'Aerosol Challenge'}); %legend 
  
            disp('HRSD-done') 
            %%unfold             
            end 
B.2 STATISTICAL ANALYSIS AUTOMATION 
Case: M166-16, M167-16, M168-16, M169-16 
%A - M166-16 - rows; see doc.  
    A = {M166_ARIMA; M166_DPI; M166_F_W_L_BAD; M166_F_W_L_BADCens; M166_F_W_L_BADSD; M166_F_W_L_CumFH; 
M166_F_W_L_CumFHCens; M166_F_W_L_EQTM; M166_F_W_L_EQTMce; M166_F_W_L_EQTMCens; M166_F_W_L_EQTMceSD; 
M166_F_W_L_EQTMcs; M166_F_W_L_EQTMcsSD; M166_F_W_L_EQTMSD; M166_F_W_L_EQTS; M166_F_W_L_EQTSc; 
M166_F_W_L_EQTScSD; M166_F_W_L_EQTSSD; M166_F_W_L_GW; M166_F_W_L_GWSD; M166_F_W_L_HR; 
M166_F_W_L_HRCens; M166_F_W_L_HRSD; M166_F_W_L_Match; M166_F_W_L_MatchSD; M166_F_W_L_MxdV; 
M166_F_W_L_MxdVCens; M166_F_W_L_MxdVSD; M166_F_W_L_Noise; M166_F_W_L_NoiseCens; M166_F_W_L_NoiseSD; 
M166_F_W_L_Num; M166_F_W_L_NumSD; M166_F_W_L_PCt; M166_F_W_L_PCtSD; M166_F_W_L_PH; M166_F_W_L_PHSD; 
M166_F_W_L_PMatch; M166_F_W_L_PMatchSD; M166_F_W_L_PRI; M166_F_W_L_PRISD; M166_F_W_L_PWdth; 
M166_F_W_L_PWdthSD; M166_F_W_L_QAT; M166_F_W_L_QATN; M166_F_W_L_QATNSD; M166_F_W_L_QATSD; 
M166_F_W_L_QMatch; M166_F_W_L_QMatchSD; M166_F_W_L_QRI; M166_F_W_L_QRISD; M166_F_W_L_QRS; 
M166_F_W_L_QRSA; M166_F_W_L_QRSASD; M166_F_W_L_QRSSD; M166_F_W_L_QTcb; M166_F_W_L_QTcbSD; 
M166_F_W_L_QTcf; M166_F_W_L_QTcfSD; M166_F_W_L_QTck; M166_F_W_L_QTckSD; M166_F_W_L_QTcm; 
M166_F_W_L_QTcmSD; M166_F_W_L_QTCt; M166_F_W_L_QTCtSD; M166_F_W_L_QTcv; M166_F_W_L_QTcvSD; 
M166_F_W_L_QTD; M166_F_W_L_QTDSD; M166_F_W_L_QTI; M166_F_W_L_QTISD; M166_F_W_L_QTMc; M166_F_W_L_QTMcSD; 
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M166_F_W_L_RH; M166_F_W_L_RHSD; M166_F_W_L_RRI; M166_F_W_L_RRISD; M166_F_W_L_SMatch; M166_F_W_L_SMatchSD; 
M166_F_W_L_STE; M166_F_W_L_STESD; M166_F_W_L_STI; M166_F_W_L_STISD; M166_F_W_L_T_Area; 
M166_F_W_L_T_AreaSD;  M166_F_W_L_T_Mean; M166_F_W_L_T_MeanCens; M166_F_W_L_T_MeanSD;  M166_F_W_L_TCt; 
M166_F_W_L_TCtSD; M166_F_W_L_TH; M166_F_W_L_THN; M166_F_W_L_THNSD; M166_F_W_L_THSD; M166_F_W_L_TMatch; 
M166_F_W_L_TMatchSD; M166_F_W_L_TP; M166_F_W_L_TpeI; M166_F_W_L_TpeISD; M166_F_W_L_TPSD; M166_F_W_L_TW; 
M166_F_W_L_TWSD; M166ModCumFH}; 
    %B - M167-16 - rows; see doc. 
    B = {M167_ARIMA; M167_DPI; M167_F_W_L_BAD; M167_F_W_L_BADCens; M167_F_W_L_BADSD; M167_F_W_L_CumFH; 
M167_F_W_L_CumFHCens; M167_F_W_L_EQTM; M167_F_W_L_EQTMce; M167_F_W_L_EQTMCens; M167_F_W_L_EQTMceSD; 
M167_F_W_L_EQTMcs; M167_F_W_L_EQTMcsSD; M167_F_W_L_EQTMSD; M167_F_W_L_EQTS; M167_F_W_L_EQTSc; 
M167_F_W_L_EQTScSD; M167_F_W_L_EQTSSD; M167_F_W_L_GW; M167_F_W_L_GWSD; M167_F_W_L_HR; 
M167_F_W_L_HRCens; M167_F_W_L_HRSD; M167_F_W_L_Match; M167_F_W_L_MatchSD; M167_F_W_L_MxdV; 
M167_F_W_L_MxdVCens; M167_F_W_L_MxdVSD; M167_F_W_L_Noise; M167_F_W_L_NoiseCens; M167_F_W_L_NoiseSD; 
M167_F_W_L_Num; M167_F_W_L_NumSD; M167_F_W_L_PCt; M167_F_W_L_PCtSD; M167_F_W_L_PH; M167_F_W_L_PHSD; 
M167_F_W_L_PMatch; M167_F_W_L_PMatchSD; M167_F_W_L_PRI; M167_F_W_L_PRISD; M167_F_W_L_PWdth; 
M167_F_W_L_PWdthSD; M167_F_W_L_QAT; M167_F_W_L_QATN; M167_F_W_L_QATNSD; M167_F_W_L_QATSD; 
M167_F_W_L_QMatch; M167_F_W_L_QMatchSD; M167_F_W_L_QRI; M167_F_W_L_QRISD; M167_F_W_L_QRS; 
M167_F_W_L_QRSA; M167_F_W_L_QRSASD; M167_F_W_L_QRSSD; M167_F_W_L_QTcb; M167_F_W_L_QTcbSD; 
M167_F_W_L_QTcf; M167_F_W_L_QTcfSD; M167_F_W_L_QTck; M167_F_W_L_QTckSD; M167_F_W_L_QTcm; 
M167_F_W_L_QTcmSD; M167_F_W_L_QTCt; M167_F_W_L_QTCtSD; M167_F_W_L_QTcv; M167_F_W_L_QTcvSD; 
M167_F_W_L_QTD; M167_F_W_L_QTDSD; M167_F_W_L_QTI;  M167_F_W_L_QTISD; M167_F_W_L_QTMc; M167_F_W_L_QTMcSD; 
M167_F_W_L_RH; M167_F_W_L_RHSD; M167_F_W_L_RRI; M167_F_W_L_RRISD; M167_F_W_L_SMatch; M167_F_W_L_SMatchSD; 
M167_F_W_L_STE; M167_F_W_L_STESD; M167_F_W_L_STI; M167_F_W_L_STISD; M167_F_W_L_T_Area; 
M167_F_W_L_T_AreaSD;  M167_F_W_L_T_Mean; M167_F_W_L_T_MeanCens; M167_F_W_L_T_MeanSD; M167_F_W_L_TCt; 
M167_F_W_L_TCtSD; M167_F_W_L_TH; M167_F_W_L_THN; M167_F_W_L_THNSD; M167_F_W_L_THSD; M167_F_W_L_TMatch; 
M167_F_W_L_TMatchSD; M167_F_W_L_TP; M167_F_W_L_TpeI; M167_F_W_L_TpeISD; M167_F_W_L_TPSD; M167_F_W_L_TW; 
M167_F_W_L_TWSD; M167ModCumFH}; 
    %C - M168-16 - rows; see doc. 
    C = {M168_ARIMA; M168_DPI; M168_F_W_L_BAD; M168_F_W_L_BADCens; M168_F_W_L_BADSD; M168_F_W_L_CumFH; 
M168_F_W_L_CumFHCens; M168_F_W_L_EQTM; M168_F_W_L_EQTMce; M168_F_W_L_EQTMCens; M168_F_W_L_EQTMceSD; 
M168_F_W_L_EQTMcs; M168_F_W_L_EQTMcsSD; M168_F_W_L_EQTMSD; M168_F_W_L_EQTS; M168_F_W_L_EQTSc; 
M168_F_W_L_EQTScSD; M168_F_W_L_EQTSSD; M168_F_W_L_GW; M168_F_W_L_GWSD; M168_F_W_L_HR; 
M168_F_W_L_HRCens; M168_F_W_L_HRSD; M168_F_W_L_Match; M168_F_W_L_MatchSD; M168_F_W_L_MxdV; 
M168_F_W_L_MxdVCens; M168_F_W_L_MxdVSD; M168_F_W_L_Noise; M168_F_W_L_NoiseCens; M168_F_W_L_NoiseSD; 
M168_F_W_L_Num; M168_F_W_L_NumSD; M168_F_W_L_PCt; M168_F_W_L_PCtSD; M168_F_W_L_PH; M168_F_W_L_PHSD; 
M168_F_W_L_PMatch; M168_F_W_L_PMatchSD; M168_F_W_L_PRI; M168_F_W_L_PRISD; M168_F_W_L_PWdth; 
M168_F_W_L_PWdthSD; M168_F_W_L_QAT; M168_F_W_L_QATN; M168_F_W_L_QATNSD; M168_F_W_L_QATSD; 
M168_F_W_L_QMatch; M168_F_W_L_QMatchSD; M168_F_W_L_QRI; M168_F_W_L_QRISD; M168_F_W_L_QRS; 
M168_F_W_L_QRSA; M168_F_W_L_QRSASD; M168_F_W_L_QRSSD; M168_F_W_L_QTcb; M168_F_W_L_QTcbSD; 
M168_F_W_L_QTcf; M168_F_W_L_QTcfSD; M168_F_W_L_QTck; M168_F_W_L_QTckSD; M168_F_W_L_QTcm; 
M168_F_W_L_QTcmSD; M168_F_W_L_QTCt; M168_F_W_L_QTCtSD; M168_F_W_L_QTcv; M168_F_W_L_QTcvSD; 
M168_F_W_L_QTD; M168_F_W_L_QTDSD; M168_F_W_L_QTI; M168_F_W_L_QTISD; M168_F_W_L_QTMc; M168_F_W_L_QTMcSD; 
M168_F_W_L_RH; M168_F_W_L_RHSD; M168_F_W_L_RRI; M168_F_W_L_RRISD; M168_F_W_L_SMatch; M168_F_W_L_SMatchSD; 
M168_F_W_L_STE; M168_F_W_L_STESD; M168_F_W_L_STI; M168_F_W_L_STISD; M168_F_W_L_T_Area; M168_F_W_L_T_AreaSD; 
M168_F_W_L_T_Mean; M168_F_W_L_T_MeanCens; M168_F_W_L_T_MeanSD;  M168_F_W_L_TCt; M168_F_W_L_TCtSD; 
M168_F_W_L_TH; M168_F_W_L_THN; M168_F_W_L_THNSD; M168_F_W_L_THSD; M168_F_W_L_TMatch; M168_F_W_L_TMatchSD; 
M168_F_W_L_TP; M168_F_W_L_TpeI; M168_F_W_L_TpeISD; M168_F_W_L_TPSD; M168_F_W_L_TW; M168_F_W_L_TWSD; 
M168ModCumFH}; 
    %C - M168-16 - rows; see doc. 
    D = {M169_ARIMA; M169_DPI; M169_F_W_D_BAD; M169_F_W_D_BADCens; M169_F_W_D_BADSD; M169_F_W_D_CumFH; 
M169_F_W_D_CumFHCens; M169_F_W_D_EQTM; M169_F_W_D_EQTMce; M169_F_W_D_EQTMCens; M169_F_W_D_EQTMceSD; 
M169_F_W_D_EQTMcs; M169_F_W_D_EQTMcsSD; M169_F_W_D_EQTMSD; M169_F_W_D_EQTS; M169_F_W_D_EQTSc; 
M169_F_W_D_EQTScSD; M169_F_W_D_EQTSSD; M169_F_W_D_GW; M169_F_W_D_GWSD; M169_F_W_D_HR; 
M169_F_W_D_HRCens; M169_F_W_D_HRSD; M169_F_W_D_Match; M169_F_W_D_MatchSD;  M169_F_W_D_MxdV; 
M169_F_W_D_MxdVCens; M169_F_W_D_MxdVSD; M169_F_W_D_Noise; M169_F_W_D_NoiseCens; M169_F_W_D_NoiseSD; 
M169_F_W_D_Num; M169_F_W_D_NumSD; M169_F_W_D_PCt; M169_F_W_D_PCtSD; M169_F_W_D_PH; M169_F_W_D_PHSD; 
M169_F_W_D_PMatch; M169_F_W_D_PMatchSD; M169_F_W_D_PRI; M169_F_W_D_PRISD; M169_F_W_D_PWdth; 
M169_F_W_D_PWdthSD; M169_F_W_D_QAT; M169_F_W_D_QATN; M169_F_W_D_QATNSD; M169_F_W_D_QATSD; 
M169_F_W_D_QMatch; M169_F_W_D_QMatchSD; M169_F_W_D_QRI; M169_F_W_D_QRISD; M169_F_W_D_QRS; 
M169_F_W_D_QRSA; M169_F_W_D_QRSASD; M169_F_W_D_QRSSD; M169_F_W_D_QTcb; M169_F_W_D_QTcbSD; 
M169_F_W_D_QTcf; M169_F_W_D_QTcfSD; M169_F_W_D_QTck; M169_F_W_D_QTckSD; M169_F_W_D_QTcm; 
M169_F_W_D_QTcmSD; M169_F_W_D_QTCt; M169_F_W_D_QTCtSD; M169_F_W_D_QTcv; M169_F_W_D_QTcvSD; 
M169_F_W_D_QTD; M169_F_W_D_QTDSD; M169_F_W_D_QTI; M169_F_W_D_QTISD; M169_F_W_D_QTMc; M169_F_W_D_QTMcSD; 
M169_F_W_D_RH; M169_F_W_D_RHSD; M169_F_W_D_RRI; M169_F_W_D_RRISD; M169_F_W_D_SMatch; M169_F_W_D_SMatchSD; 
M169_F_W_D_STE; M169_F_W_D_STESD; M169_F_W_D_STI; M169_F_W_D_STISD; M169_F_W_D_T_Area; 
M169_F_W_D_T_AreaSD;  M169_F_W_D_T_Mean; M169_F_W_D_T_MeanCens; M169_F_W_D_T_MeanSD;  M169_F_W_D_TCt; 
M169_F_W_D_TCtSD; M169_F_W_D_TH; M169_F_W_D_THN; M169_F_W_D_THNSD; M169_F_W_D_THSD; M169_F_W_D_TMatch; 
M169_F_W_D_TMatchSD; M169_F_W_D_TP; M169_F_W_D_TpeI; M169_F_W_D_TpeISD; M169_F_W_D_TPSD; M169_F_W_D_TW; 
M169_F_W_D_TWSD; M169ModCumFH}; 
  
        %Period Generation 
            %Days 
            for i = 1:1 
                     disDPI_166 = [-3 -2 -1 0 1 2 3 4 5 6 7 8]; 
                     realDPI_167 =[]; 
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                     indexGenericDayMat_166 = []; 
                     for i=1:1:length(disDPI_166) 
                     desDay = disDPI_166(i); 
                     tmp = abs(A{2}-desDay); 
                     [idx1 idxa] = min(tmp); 
                     indexGenericDayMat_166(i) = idxa; 
                     closest = A{2}(idxa); 
                     realDPI_167(i) = closest; 
                     end 
                    disDPI_167 = [-3 -2 -1 0 1 2 3 4 5 6 7 8]; 
                    realDPI_167 =[]; 
                    indexGenericDayMat_167 = []; 
                    for i=1:1:length(disDPI_167) 
                    desDay = disDPI_167(i); 
                    tmp = abs(B{2}-desDay); 
                    [idx1 idxb] = min(tmp); 
                    indexGenericDayMat_167(i) = idxb; 
                    closest = B{2}(idxb); 
                    realDPI_167(i) = closest; 
                    end 
                    disDPI_168 = [-3 -2 -1 0 1 2 3 4 5 6 7 8]; 
                    realDPI_168 =[]; 
                    indexGenericDayMat_168 = []; 
                    for i=1:1:length(disDPI_168) 
                    desDay = disDPI_168(i); 
                    tmp = abs(C{2}-desDay); 
                    [idx1 idxc] = min(tmp); 
                    indexGenericDayMat_168(i) = idxc; 
                    closest = C{2}(idxc); 
                    realDPI_168(i) = closest; 
                    end 
                    disDPI_169 = [-3 -2 -1 0 1 2 3 4 5 6 7 8]; 
                    realDPI_169 =[]; 
                    indexGenericDayMat_169 = []; 
                    for i=1:1:length(disDPI_169) 
                    desDay = disDPI_169(i); 
                    tmp = abs(D{2}-desDay); 
                    [idx1 idxd] = min(tmp); 
                    indexGenericDayMat_169(i) = idxd; 
                    closest = D{2}(idxd); 
                    realDPI_169(i) = closest; 
                    end 
            end 
            %Periods 
            kk = 1; 
            while kk<5 
            switch kk 
                case 1 
                     disPre_166 = [-3 -2 -1]; 
                        Pre166 = M166_DPI(indexGenericDayMat_166(1):indexGenericDayMat_166(3)); 
                     disPost_166 = [0 1 2 3 4 5 6 7 8];  
                        Post166 = M166_DPI(indexGenericDayMat_166(3):indexGenericDayMat_166(12)); 
                case 2 
                     disPre_167 = [-3 -2 -1]; 
                        Pre167 = M167_DPI(indexGenericDayMat_167(1):indexGenericDayMat_167(3)); 
                     disPost_167 = [0 1 2 3 4 5 6 7 8];  
                        Post167 = M167_DPI(indexGenericDayMat_167(3)+1:indexGenericDayMat_167(12)); 
                case 3 
                     disPre_168 = [-3 -2 -1]; 
                        Pre168 = M168_DPI(indexGenericDayMat_168(1):indexGenericDayMat_168(3)); 
                     disPost_168 = [0 1 2 3 4 5 6 7 8]; 
                        Post168 = M168_DPI(indexGenericDayMat_168(3)+1:indexGenericDayMat_168(12)); 
                case 4 
                     disPre_169 = [-3 -2 -1]; 
                        Pre169 = M169_DPI(indexGenericDayMat_169(1):indexGenericDayMat_169(3)); 
                     disPost_169 = [0 1 2]; 
                        Post169 = M169_DPI(indexGenericDayMat_169(3)+1:indexGenericDayMat_169(6)); 
                     disFeb_169 = [3 4 5 6 7 8]; 
                        Feb169 = M169_DPI(indexGenericDayMat_169(6)+1:indexGenericDayMat_169(12)); 
            end 
            kk = kk+1; 
            end 
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B.2.1 One Way ANOVA and T-Tests 
Case: Heart Rate, M166-16, M168-16, M169-16 
 %values,means,stdev 
                for i=1:1 
                HR_166_DPIly = zeros(length(indexGenericDayMat_166)-1,3); 
                for i=1:1:length(indexGenericDayMat_166)-1              
                  HR_166_DPIly(i,1) = mean(M166_F_W_L_HRCens(indexGenericDayMat_166(i):indexGenericDayMat_166(i+1))); 
                  HR_166_DPIly(i,2) = std(M166_F_W_L_HRCens(indexGenericDayMat_166(i):indexGenericDayMat_166(i+1))); 
                  HR_166_DPIly(i,3) =  indexGenericDayMat_166(i+1)-indexGenericDayMat_166(i); 
                end 
                HR_167_DPIly = zeros(length(indexGenericDayMat_167)-1,3); 
                for i=1:1:length(indexGenericDayMat_167)-1              
                  HR_167_DPIly(i,1) = mean(M167_F_W_L_HRCens(indexGenericDayMat_167(i):indexGenericDayMat_167(i+1))); 
                  HR_167_DPIly(i,2) = std(M167_F_W_L_HRCens(indexGenericDayMat_167(i):indexGenericDayMat_167(i+1))); 
                  HR_167_DPIly(i,3) =  indexGenericDayMat_167(i+1)-indexGenericDayMat_167(i); 
                end 
                HR_168_DPIly = zeros(length(indexGenericDayMat_168)-1,3); 
                for i=1:1:length(indexGenericDayMat_168)-1              
                  HR_168_DPIly(i,1) = mean(M168_F_W_L_HRCens(indexGenericDayMat_168(i):indexGenericDayMat_168(i+1))); 
                  HR_168_DPIly(i,2) = std(M168_F_W_L_HRCens(indexGenericDayMat_168(i):indexGenericDayMat_168(i+1))); 
                  HR_168_DPIly(i,3) =  indexGenericDayMat_168(i+1)-indexGenericDayMat_168(i); 
                end 
                 HR_169_DPIly = zeros(length(indexGenericDayMat_169)-1,3); 
                for i=1:1:length(indexGenericDayMat_169)-1              
                  HR_169_DPIly(i,1) = mean(M169_F_W_D_HRCens(indexGenericDayMat_169(i):indexGenericDayMat_169(i+1))); 
                  HR_169_DPIly(i,2) = std(M169_F_W_D_HRCens(indexGenericDayMat_169(i):indexGenericDayMat_169(i+1))); 
                  HR_169_DPIly(i,3) =  indexGenericDayMat_169(i+1)-indexGenericDayMat_169(i); 
                end 
                %values 
                HR_DPIlyMaster = [HR_166_DPIly(:,1), HR_167_DPIly(:,1), HR_168_DPIly(:,1), HR_169_DPIly(:,1)];     
                HR_166 = {}; 
                for i=1:1:length(indexGenericDayMat_166)-1 
                  HR_166{i} = (M166_F_W_L_HRCens(indexGenericDayMat_166(i):15:indexGenericDayMat_166(i+1))); 
                end 
                HR_167 = {}; 
                for i=1:1:length(indexGenericDayMat_167)-1              
                  HR_167{i} = (M167_F_W_L_HRCens(indexGenericDayMat_167(i):15:indexGenericDayMat_167(i+1))); 
                end 
                  HR_168 = {}; 
                for i=1:1:length(indexGenericDayMat_168)-1              
                  HR_168{i} = (M166_F_W_L_HRCens(indexGenericDayMat_168(i):15:indexGenericDayMat_168(i+1))); 
                end 
                HR_169 = {}; 
                for i=1:1:length(indexGenericDayMat_169)-1              
                  HR_169{i} = (M169_F_W_D_HRCens(indexGenericDayMat_169(i):indexGenericDayMat_169(i+1))); 
                end 
             end    
                %per-diem-analysis-ANOVA            
                for i=1:1 
                 
                for  i = 1:1:11 
                transpose = HR_166{1,i}'; 
                padHR166 = 5000-length(HR_166{1,i}); 
                NaNHR166 = NaN(1,padHR166); 
                transpose = [transpose NaNHR166]; 
                HR_166{1,i} = transpose'; 
                i = i+1; 
                end      
                HR166 = [HR_166{1,1}, HR_166{1,2}, HR_166{1,3}, HR_166{1,4}, HR_166{1,5}, HR_166{1,6}, HR_166{1,7}, HR_166{1,8}, 
HR_166{1,9}, HR_166{1,10}, HR_166{1,11}];  
                Time166 = disDPI_166(1:11)'; 
                [pHR166 tblHR166 statsHR166] = anova1(HR166) 
                statsHR166.gnames = ['-3dpi'; '-2dpi'; '-1dpi'; '-0dpi'; '+1dpi'; '+2dpi'; '+3dpi'; '+4dpi'; '+5dpi'; '+6dpi'; '+7dpi']; 
                multcompare(statsHR166); 
                title('M166 HR DPI Pairwise Comparisons') 
                 
                for  i = 1:1:11 
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                transpose = HR_168{1,i}'; 
                padHR168 = 5000-length(HR_168{1,i}); 
                NaNHR168 = NaN(1,padHR168); 
                transpose = [transpose NaNHR168]; 
                HR_168{1,i} = transpose'; 
                i = i+1; 
                end  
                HR168 = [HR_168{1,1}, HR_168{1,2}, HR_168{1,3}, HR_168{1,4}, HR_168{1,5}, HR_168{1,6}, HR_168{1,7}, HR_168{1,8}, 
HR_168{1,9}, HR_168{1,10}, HR_168{1,11}];  
                Time168 = disDPI_168(1:11)'; 
                [pHR168 tblHR168 statsHR168] = anova1(HR168) 
                statsHR168.gnames = ['-3dpi'; '-2dpi'; '-1dpi'; '-0dpi'; '+1dpi'; '+2dpi'; '+3dpi'; '+4dpi'; '+5dpi'; '+6dpi'; '+7dpi']; 
                multcompare(statsHR168); 
                title('M168 HR DPI Pairwise Comparisons') 
                 
                for  i = 1:1:11 
                transpose = HR_169{1,i}'; 
                padHR169 = 5000-length(HR_169{1,i}); 
                NaNHR169 = NaN(1,padHR169); 
                transpose = [transpose NaNHR169]; 
                HR_169{1,i} = transpose'; 
                i = i+1; 
                end  
                HR169 = [HR_169{1,1}, HR_169{1,2}, HR_169{1,3}, HR_169{1,4}, HR_169{1,5}, HR_169{1,6}, HR_169{1,7}, HR_169{1,8}, 
HR_169{1,9}, HR_169{1,10}, HR_169{1,11}];  
                Time169 = disDPI_169(1:11)'; 
                [pHR169 tblHR169 statsHR169] = anova1(HR169) 
                statsHR169.gnames = ['-3dpi'; '-2dpi'; '-1dpi'; '-0dpi'; '+1dpi'; '+2dpi'; '+3dpi'; '+4dpi'; '+5dpi'; '+6dpi'; '+7dpi']; 
                multcompare(statsHR169); 
                title('M169 HR DPI Pairwise Comparisons') 
 
PreHRper166 = M166_F_W_L_HRCens(indexGenericDayMat_166(1):15:indexGenericDayMat_166(3));  
                    PostHRper166 = M166_F_W_L_HRCens(indexGenericDayMat_166(3)+1:15:indexGenericDayMat_166(12)); 
                    [hHRper166,pHRper166,ciHRper166,statsHRper166] = ttest2(PreHRper166,PostHRper166) 
                     
                    PreHRper168 = M168_F_W_L_HRCens(indexGenericDayMat_168(1):15:indexGenericDayMat_168(3));  
                    PostHRper168 = M168_F_W_L_HRCens(indexGenericDayMat_168(3)+1:15:indexGenericDayMat_168(12)); 
                    [hHRper168,pHRper168,ciHRper168,statsHRper168] = ttest2(PreHRper168,PostHRper168) 
                 
                    PreHRper169 = M169_F_W_D_HRCens(indexGenericDayMat_169(1):15:indexGenericDayMat_169(3));  
                    PostHRper169 = M169_F_W_D_HRCens(indexGenericDayMat_169(3)+1:15:indexGenericDayMat_169(6)); 
                    FebHRper169 = M169_F_W_D_HRCens(indexGenericDayMat_169(6)+1:15:indexGenericDayMat_169(12)); 
                      
                         transpose = PreHRper169'; 
                         padHR169 = 500-length(PreHRper169); 
                         NaNHR169 = NaN(1,padHR169); 
                         transpose = [transpose NaNHR169]; 
                         PreHRper169 = transpose'; 
                         transpose = PostHRper169'; 
                         padHR169 = 500-length(PostHRper169); 
                         NaNHR169 = NaN(1,padHR169); 
                         transpose = [transpose NaNHR169]; 
                         PostHRper169 = transpose'; 
                         transpose = FebHRper169'; 
                         padHR169 = 500-length(FebHRper169); 
                         NaNHR169 = NaN(1,padHR169); 
                         transpose = [transpose NaNHR169]; 
                         FebHRper169 = transpose'; 
                        
                    HRper169 = [PreHRper169 PostHRper169 FebHRper169]; 
                    [pHRper169 tblHRper169 statsHRper169] = anova1(HRper169) 
                    statsHRper169.gnames = ['Pre '; 'Post'; 'Feb ']; 
                    figure; 
                    multcompare(statsHRper169); 
                    title('M169 HR Period Pairwise Comparisons') 
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B.2.2 Repeated Measures ANOVA 
Case: Heart Rate, M166-16, M168-16, M169-16 
 
TimeVec = (1:1:5000)'; 
                tHR166 = table(TimeVec, HR_166{1,1}, HR_166{1,2}, HR_166{1,3}, HR_166{1,4}, HR_166{1,5}, HR_166{1,6}, HR_166{1,7}, 
HR_166{1,8}, HR_166{1,9}, HR_166{1,10}, HR_166{1,11},'VariableNames', 
{'Time','dpin3','dpin2','dpin1','dpin0','dpip1','dpip2','dpip3','dpip4','dpip5','dpip6', 'dpip7'}); 
                MeasHR166 = table([1 2 3 4 5 6 7 8 9 10 11]', 'Variablenames', {'HR'});  
                rmHR166 = fitrm(tHR166, 'dpin3-dpip7~Time', 'WithinDesign', MeasHR166); 
                ranovatbl = ranova(rmHR166) 
                rmHR166.Coefficients 
                rmHR166.Covariance 
                 
                HR_168{1,8}(1,1) = 0; 
                HR_168{1,8}(2,1) = 0; 
                HR_168{1,8}(3,1) = 0; 
                tHR168 = table(TimeVec, HR_168{1,1}, HR_168{1,2}, HR_168{1,3}, HR_168{1,4}, HR_168{1,5}, HR_168{1,6}, HR_168{1,7}, 
HR_168{1,8}, HR_168{1,9}, HR_168{1,10}, HR_168{1,11},'VariableNames', 
{'Time','dpin3','dpin2','dpin1','dpin0','dpip1','dpip2','dpip3','dpip4','dpip5','dpip6', 'dpip7'}); 
                MeasHR168 = table([1 2 3 4 5 6 7 8 9 10 11]', 'Variablenames', {'HR'});  
                rmHR168 = fitrm(tHR168, 'dpin3-dpip7~Time', 'WithinDesign', MeasHR168); 
                ranovatbl = ranova(rmHR168) 
                rmHR168.Coefficients 
                rmHR168.Covariance 
                 
                tHR169 = table(TimeVec, HR_169{1,1}, HR_169{1,2}, HR_169{1,3}, HR_169{1,4}, HR_169{1,5}, HR_169{1,6}, HR_169{1,7}, 
HR_169{1,8}, HR_169{1,9}, HR_169{1,10}, HR_169{1,11},'VariableNames', 
{'Time','dpin3','dpin2','dpin1','dpin0','dpip1','dpip2','dpip3','dpip4','dpip5','dpip6', 'dpip7'}); 
                MeasHR169 = table([1 2 3 4 5 6 7 8 9 10 11]', 'Variablenames', {'HR'});  
                rmHR169 = fitrm(tHR169, 'dpin3-dpip7~Time', 'WithinDesign', MeasHR169); 
                ranovatbl = ranova(rmHR169) 
                rmHR169.Coefficients 
                rmHR169.Covariance 
 
B.3 FREQUENCY SPECTRUM ANALYSIS 
B.3.1 Window Visualization Tool 
Case: Heart Rate, M166-16, M168-16, M169-16 
 
M166_HRfft_Pre = M166_F_W_L_HRCens(indexGenericDayMat_166(1):indexGenericDayMat_166(4)); 
M166_HRfft_Post = M166_F_W_L_HRCens(indexGenericDayMat_166(5):indexGenericDayMat_166(12)); 
wvtool(M166_HRfft_Pre,M166_HRfft_Post) 
M167_HRfft_Pre = M167_F_W_L_HRCens(indexGenericDayMat_167(1):indexGenericDayMat_167(4)); 
M167_HRfft_Post = M167_F_W_L_HRCens(indexGenericDayMat_167(5):indexGenericDayMat_167(12)); 
wvtool(M167_HRfft_Pre,M167_HRfft_Post) 
M168_HRfft_Pre = M168_F_W_L_HRCens(indexGenericDayMat_168(1):indexGenericDayMat_168(4)); 
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M168_HRfft_Post = M168_F_W_L_HRCens(indexGenericDayMat_168(5):indexGenericDayMat_168(12)); 
wvtool(M168_HRfft_Pre,M168_HRfft_Post) 
M169_HRfft_Pre = M169_F_W_D_HRCens(indexGenericDayMat_169(1):indexGenericDayMat_169(4)); 
M169_HRfft_Post = M169_F_W_D_HRCens(indexGenericDayMat_169(5):indexGenericDayMat_169(6)); 
M169_HRfft_Feb = M169_F_W_D_HRCens(indexGenericDayMat_169(7):indexGenericDayMat_169(12)); 
wvtool(M169_HRfft_Pre,M169_HRfft_Post,M169_HRfft_Feb); 
 
B.4 HEART RATE VARIABILITY 
B.4.1 Poincare Plot Overlay Generation 
Case: HRV, M169-16 
 
 
M169HRVser = {}; 
            transpose1 = M169_F_W_D_HRV1'; 
            transpose2 = M169_F_W_D_HRV2'; 
            M169HRVX = nan(1440,11); 
            M169HRVY  = nan(1440,11); 
            M169HRVDPIgrpser = ['-3dpi','-2dpi','-1dpi','0dpi','1dpi','2dpi','3dpi','4dpi','5dpi','6dpi','7dpi']; 
            for i=1:1:11 
            M169HRVser{1,i} =   transpose1(indexGenericDayMat_169(i):indexGenericDayMat_169(i+1)); 
            M169HRVser{2,i} =   transpose2(indexGenericDayMat_169(i):indexGenericDayMat_169(i+1));       
                for j = 1:1:length(M169HRVser{1,i}) 
                        M169HRVX(j,i) = M169HRVser{1,i}(1,j); 
                end 
  
                for k = 1:1:length(M169HRVser{2,i}) 
                        M169HRVY(k,i) = M169HRVser{2,i}(1,k); 
                end 
            end     
        M169HRV = []; 
            transpose1 = M169_F_W_D_HRV1'; 
            transpose2 = M169_F_W_D_HRV2'; 
            M169HRV(:,1) = transpose1(indexGenericDayMat_169(1)+1:indexGenericDayMat_169(12))'; 
            M169HRV(:,2) = transpose2(indexGenericDayMat_169(1)+1:indexGenericDayMat_169(12))'; 
            M169HRVDPIgrp = zeros(length(M169HRV(:,1)'),1); 
            for j = 1:1:11 
            for i= indexGenericDayMat_169(j):1:(indexGenericDayMat_169(j+1)-1) 
                M169HRVDPIgrp(i,1) = j-4; 
            end   
            end 
            transposegrp = M169HRVDPIgrp'; 
            M169HRVDPIgrp = transposegrp(indexGenericDayMat_169(1):1:length(transposegrp))'; 
            figure; 
            scatterhist(M169HRV(:,1),M169HRV(:,2),'Group',M169HRVDPIgrp,'Kernel','on', 'Color','ccckkkrrrrr','Legend','on');  
            hold on; 
            xlabel('RRI_n (ms)'); 
            ylabel('RRI_n_+_1 (ms)'); 
            title('M169-16 HRV'); 
            annotation('textbox',[0.063 0.107142857142857 0.0829285714285714 
0.104761904761905],'String',{'Days','Post','Infection'},'FitBoxToText','on'); 
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B.4.2 Probability Density – One Way ANOVA 
Case: HRV, M169-16 
 
M169HRVoneWay= zeros(100,11); 
            for i = 1:1:11 
                M169HRVoneWay(:,i) = ksdensity(M169HRVX(:,i))'; 
                  
            end 
                [pHRV169 tblHRV169 statsHRV169] = anova1(M169HRVoneWay) 
                statsHRV169.gnames = ['-3dpi'; '-2dpi'; '-1dpi'; '-0dpi'; '+1dpi'; '+2dpi'; '+3dpi'; '+4dpi'; '+5dpi'; '+6dpi'; '+7dpi']; 
                figure; 
                multcompare(statsHRV169); 
                title('M169 HRV DPI Pairwise Comparisons') 
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